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Tuberculosis (TB) is a lung disease caused by Mycobacterium tuberculosis (Mtb), which was 
responsible for 1.6 million deaths in 2017. The only vaccine against TB; bacille Calmette 
Guérin (BCG), protects against miliary and meningeal TB in neonates and offers some 
protection in animal models. However, BCG provides unreliable protection against the 
predominant form of TB; adult pulmonary TB. Consequently, a new more efficacious vaccine 
against adult pulmonary TB is urgently required.  
A major challenge preventing the development of a new vaccine against adult pulmonary TB 
is that very little is known about which cell types and memory responses contribute to protection 
against mycobacterial infections following BCG vaccination. Recent evidence has suggested 
that innate lymphoid cells (ILCs), a subset of immune cells, may contribute to the generation 
of a protective immune response against Mtb since ILC1 and ILC3 subsets have been found to 
upregulate the production of the cytokine; interferon gamma and accumulate in the lungs of 
BCG-inoculated mice compared to naïve mice. Consequently, the aim of this project was to 
identify whether ILC1s and ILC3s isolated from the lungs of BCG-inoculated mice could 
inhibit the growth of mycobacteria in vitro, which would indicate directly for the first time 
whether ILCs can protect against mycobacterial infections.  
Flow cytometry was used to identify ILC subsets based on the expression of surface markers 
to enable sorting of live ILCs. However, poor fidelity between surface marker expression and 
the canonical ILC subset transcription factor expression, which is the gold-standard method for 
categorising ILCs, meant that ILC subsets could not be confidently categorised. Additionally, 
insufficient numbers of ILCs in the lungs of BCG-inoculated mice meant that it was not feasible 
to sort live ILC subsets. Instead, total ILCs isolated from the lungs of BCG-inoculated mice 
were used to establish an in vitro mycobacterial growth inhibition assay, whereby total ILCs 
sorted by flow cytometry were cultured with BCG-infected splenocytes. The ability of ILCs to 
enhance mycobacterial killing was measured by enumerating BCG colony forming units when 
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the cultures were plated onto agar. Although sorting and cultures were successful, there was 
high variability in BCG colony forming units per mL detected between technical replicates and 
no enhancement in splenocyte killing of mycobacteria was detected when ILCs were cultured 
with BCG-infected splenocytes compared to when BCG-infected splenocytes were cultured 
alone. These findings indicate that further optimisation of the in vitro mycobacterial growth 
inhibition assay is required to reduce the variability and that alternative approaches such as 
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Tuberculosis (TB) is predominantly a pulmonary disease caused by Mycobacterium 
tuberculosis (Mtb) (1). Although drug susceptible TB is curable, TB is highly infectious and 
results in significant mortality and disability worldwide. Innate lymphoid cells (ILCs) are a 
recently discovered subset of immune cells that may possess the ability to generate a protective 
immune response against Mtb infections (2). Consequently, it is important to determine whether 
ILCs can inhibit the growth of mycobacteria, as this would indicate directly for the first time 
whether ILCs can elicit a protective immune response against mycobacteria. If ILCs are 
discovered to inhibit the growth of mycobacteria in the future vaccines against adult pulmonary 
TB could be designed to enhance ILC derived protective immune responses.  
1.1 Pulmonary Tuberculosis Infection and Disease 
Patients with active TB transmit Mtb via coughing, resulting in the release of aerosols and 
droplets containing Mtb bacilli which can be inhaled into the lungs of an uninfected individual 
(3). Some Mtb infected individuals have been discovered to successfully clear Mtb via early 
host innate immune responses (4). However, 5-10% of Mtb infected individuals will develop 
active TB (5). Clinical signs and symptoms of active TB include fatigue, weight loss, low grade 
fever, night sweats, coughing and pulmonary fibrosis (3). Approximately 70% of active TB 
patients will die within 10 years if they do not receive treatment (6). The other 85-90% of 
patients who are not able to clear Mtb via early host innate immune responses develop latent 
TB whereby, viable but non-replicating Mtb are enclosed within immune cell structures known 
as granulomas (3). Patients with latent TB are non-infectious and asymptomatic. Mtb can 
remain in this latent state for a lifetime, however, in 5-10% of latent TB patients their immune 
systems can no longer supress the bacteria and latent TB can re-activate and disseminate 
throughout the respiratory tract resulting in the development of active TB (3).  
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1.2 Epidemiology of Tuberculosis  
TB is the world’s deadliest infectious disease, causing 1.6 million deaths in 2017 (7). Up to one 
third of the world’s population is infected with latent Mtb (1). In 2017, there were 10 million 
new cases of TB of which two thirds of these cases originated from eight highly populated 
countries that have poor control of TB and substandard healthcare systems, including China, 
India, and Pakistan (7). TB also exists in developed countries, such as New Zealand, where 282 
new cases were reported in 2016 (8). 
1.3 Current Medical Treatments and Prevention Strategies for 
Tuberculosis 
1.3.1 Current vaccine against TB 
The bacillus Calmette-Guérin (BCG) vaccine, an attenuated form of Mycobacterium bovis, has 
been used since 1921 to prevent TB (9). Although the BCG vaccine can confer protection 
against miliary TB and meningeal TB in neonates and infants, the protective efficacy of BCG 
against the predominant form of TB; adult pulmonary TB is highly variable ranging from 0-
80% across studies (10,11). Inconsistencies in the protective efficacy of BCG can be attributed 
to BCG strain variability, modulation of the immune system via co-infection with viruses or 
helminths, poor nutrition and exposure to non-tuberculous mycobacteria (12,13). As a result of 
the variability in BCG protective efficacy observed across trials it is widely agreed that BCG is 
insufficient to prevent against adult pulmonary TB and that a new vaccine is urgently required 
(9). 
1.3.2 Treatment for TB 
Drug susceptible TB can be treated with a six month course of first-line antibiotics: isoniazid, 
rifampicin, pyrazinamide and ethambutol (7). During the initial two months of this course of 
treatment, patients are required to take a daily combination of isoniazid, rifampicin and 
pyrazinamide with or without ethambutol daily. Over the remaining four months patients are 
recommended to take isoniazid in combination with rifampicin daily (14). 
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A fundamental issue with the current antibiotic treatment regimen is the long duration of 
therapy which can lead to low patient adherence. This can result in the generation of multi-drug 
resistant (MDR-TB) and extensively drug resistant (XDR-TB) Mtb strains. MDR-TB Mtb 
strains are resistant to at least two first-line TB antibiotics, commonly isoniazid and rifampicin. 
XDR-TB Mtb strains are not only resistant to isoniazid and rifampicin, but are also resistant to 
at least one fluoroquinolone and one second-line injectable drug (15,16). 
Isoniazid, rifampicin and ethambutol exhibit bactericidal and bacteriostatic effects against 
replicating Mtb, whereas, pyrazinamide targets non-replicating mycobacteria. Briefly: isoniazid 
inhibits mycolic acid synthesis (a major TB cell wall component); rifampicin inhibits the 
elongation of mycobacterial transcription; ethambutol prevents the polymerisation of 
mycobacterial cell wall component, arabinogalactan; and pyrazinamide is believed to interrupt 
the cell membrane potential and membrane transport (17–20). Since, Mtb is an extremely slow 
growing bacteria that can remain dormant in a nonreplicating state, the bactericidal activity of 
antibiotics that target cell growth or division is limited to replicating bacteria (21). As dormant 
cells periodically re-activate over the course of months the number of Mtb colonies will slowly 
decline in the presence of isoniazid, rifampicin and ethambutol that target active metabolic 
process as well as pyrazinamide (21). Therefore, long term antibiotic therapy is required to cure 
TB.  
With rising cases of drug resistant TB and challenging multi-antibiotic treatment regimens, 
controlling TB solely with antibiotics is no longer sufficient. Consequently, there has been an 
increased focus in TB vaccine development since vaccine induced immune responses are 
protective even against antibiotic resistant Mtb strains (22,23). Therefore, it is critical to 
continue to study the immune response to TB to develop a new, safe and efficacious vaccine to 
protect against adult pulmonary TB.  
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1.4 Immune Response to Tuberculosis 
The host immune response to TB is vastly complex involving both the adaptive and innate 
immune responses (1). The innate immune response, executed by innate cells, provides a rapid 
but nonspecific response. In comparison, the adaptive immune response generated by CD4+ and 
CD8+ T cells and B cells, is more specific but slower to develop and respond to infections.  
1.4.1 Innate immune response and the activation of the adaptive immune response…………. 
Upon inhalation, aerosols containing Mtb bacilli can travel to the lower respiratory tract and 
reach the alveoli (1). Once in the alveoli, pattern associated molecular patterns, such as Mtb 
glycolipids and carbohydrates, are recognised by pattern recognition receptors on a range of 
innate cells including alveolar macrophages, interstitial macrophages and dendritic cells (DCs) 
(24). Following the recognition of Mtb, non-specific binding and phagocytosis of Mtb occurs. 
Internalisation of Mtb also triggers the production of cytokines, chemokines and antimicrobial 
molecules and peptides including inducible nitric oxide synthase, tumor necrosis factor alpha 
(TNFα) and interferon gamma (IFNγ) which are critical for bacterial control and recruitment of 
immune cells (1).  
Infected DCs migrate to the lymph nodes and present Mtb antigens on major histocompatibility 
complex (MHC) I and II to naïve T cells (25). Two to three weeks after the initial infection, 
activated antigen specific T cells migrate back to the primary site of infection, to interact with 
infected macrophages and secrete IFNγ (26).  
IFNγ plays a number of key roles during Mtb infections, acting on innate phagocytic cells, 
including promoting microtubule-associated proteins 1A/1B light chain 3B (LC3) associated 
autophagy, whereby, the LC3 decorated phagosome containing Mtb matures into an 
autolysosome with enhanced bactericidal properties, killing Mtb (27,28). IFNγ and TNFα act 
synergistically to activate macrophages resulting in the upregulation of over 200 genes, some 
of which are involved in the production of nitric oxide and oxygen free radicals which enhance 
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intracellular mycobacterial killing (29). Additionally, IFNγ can enhance mycobacterial antigen 
presentation via upregulating MHCI and MHCII molecules on antigen presenting cells (29).  
1.4.2 Evasion of host immune responses 
Mtb is able to survive intracellularly in macrophages by preventing phagolysosome fusion, thus 
avoiding lysis (30). The exact mechanisms by which Mtb prevents phagosome maturation are 
not fully understood; however, a tyrosine phosphatase secreted by Mtb has been discovered to 
bind to the H subunit of macrophage vacuolar-H+-ATPase machinery inhibiting the 
acidification of the vacuole (31). Mtb can become ‘invisible’ to the immune system by living 
intracellularly, reducing the therapeutic effects of vaccination and antibodies and making it 
difficult to develop a new efficacious vaccines against TB.  
1.4.3 Granuloma formation  
TNFα can drive immune cell recruitment, which is required for the formation of granulomas 
(29). A granuloma consists of a core of infected macrophages surrounded by lymphocytes and 
fibroblasts, which act as a peripheral fibrotic capsule (1). The centre of a granuloma is hypoxic 
and was thought to be hostile to Mtb (32). It is now understood that latent Mtb can survive in a 
metabolically altered state even within the hypoxic environment of the granuloma and can 
eventually re-activate and spread freely throughout the respiratory tract (33).  
1.5 Innate Lymphoid Cells 
ILCs have only recently been formally identified as an immune cell subset and are broadly 
categorised into three groups: ILC1s, ILC2s, and ILC3s, which roughly mirror the CD4+ T cell 
effector phenotypes: Th1, Th2 and Th17, respectively (34). ILCs are derived from the common 
lymphoid progenitor, but unlike T and B cells that are stimulated by antigens, ILCs lack antigen 
specific receptors. Instead, ILCs are stimulated by cytokines, danger signals or pathogen 
derived signals at the site of infection (35,36). In the mucosal tissues of the lungs, ILCs may 
play a role in the first line of defense against pathogens (35,36). The mechanisms behind ILC 
derived protection are still being discovered and very few research groups have studied ILCs 
 6 
in relation to TB. Therefore, it is relevant to discover whether ILCs exhibit a protective role 
against mycobacterial infections.   
1.5.1  Group 1 ILCs 
Group 1 ILCs comprise of ILC1s and natural killer (NK) cells. ILC1s and NK cells are 
identified by transcription factor expression as ILC1s are T-bet + (T-box 21), whereas, NK cells 
are T-bet+ and Eomes+; however, some ILC1 populations have also been shown to express 
Eomes (37). Group 1 ILCs are known to generate immune responses against viruses and 
intracellular bacteria (38). Both ILC1s and NK cells are activated by IL-15, IL-12 and IL-18 
cytokines produced by myeloid cells or non-hemopoietic cells (38). In response to activation 
ILC1s and NK cells produce IFNγ and TNFα (see Table 1) (38). IFNγ can activate myeloid 
cells to produce reactive oxygen and nitrogen species and improve MHC derived antigen 
presentation, resulting in the enhancement of host immune responses against viruses and 
intracellular bacteria (39) Therefore, group 1 ILCs may also help protect against intracellular 
mycobacterial infections. 
1.5.2 Group 2 ILCs 
ILC2s are transcriptionally regulated by GATA3. Inducible Cre GATA3 knock-out (KO) mice 
produced significantly less type 2 cytokines: IL-5 and IL-13, in comparison to GATA3-
suffcient mice, indicating that GATA3 is required for an ILC2 phenotype to occur (40). In 
addition to GATA3, T-cell factor 1, B-cell lymphoma 11b, RAR related orphan receptor (ROR) 
alpha, ETS1 and inhibitor of DNA binding 2 (Id2) transcription factors also contribute to the 
transcriptional program of group 2 ILCs (34). Helminths such as Schistosoma mansoni, cause 
tissue damage in the lung and gut resulting in the release of epithelial derived alarmin cytokines: 
IL-33, IL-25 and thymic stromal lymphopoietin (TSLP) which activate ILC2s (41). Activated 
ILC2s respond to helminth infections by producing IL-5, IL-6, IL-9 and IL-13 cytokines similar 
to that of a T helper 2 immune response (see Table 1) (34). IL-5 can induce eosinophil 
infiltration, while IL-13 can stimulate mucous production by goblet cells and stimulate smooth 
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muscle contractions of the gut, which aid in the clearance of helminths (42,43). In addition to 
their protective effects against helminth infections, ILC2s also produce epidermal growth factor 
amphiregulin which is involved in tissue repair and lung epithelial barrier integrity and 
function, therefore, IL2s may play an important role in restoring epithelial airway integrity 
during TB infections (44). However, ILC2s were not expected to enhance mycobacterial growth 
inhibition as ILC2s have not been discovered to produce cytokines, such as IFNγ, that are 
involved in enhancing mycobacterial clearance. 
1.5.3 Group 3 ILCs 
Group 3 ILCs are distinguished from other ILC subsets due to the expression of the transcription 
factor; RORγt (45). Group 3 ILCs comprise of lymphoid-tissue-inducer cells (LTi) and natural-
cytotoxic receptor (NCR) positive and negative ILC3s. LTi cells play an essential role in the 
development of the lymph nodes and Peyer’s patches (34). Group 3 ILCs are activated by IL-
23 and IL-1β cytokines and in response produce IL-22 (see Table 1) (45). IL-22-producing LTi 
cells have been shown to help protect against extracellular Citrobacter rodentium infection in 
mice as IL-22 enhances the production of antimicrobial cytokines produced by epithelial cells 
(46,47). In addition to IL-22, NCR- ILC3s, also produce IL-17 when activated. IL-22 and IL-
17 stimulate epithelial cells to upregulate the production of antimicrobial molecules and 
proinflammatory mediators, which aid in the recruitment of neutrophils to the site of infection 
(48). Neutrophils can kill mycobacteria via the production of reactive oxygen species, therefore, 
ILC3s may help to control primary mycobacterial infections by enhancing early neutrophil 
recruitment (49). 
1.5.4 Abundance of ILC subsets found in the lung   
ILC2s are the main ILC subset found in the lungs of mice, however, ILCs are extremely rare 
with ILC2s only contributing to 0.4-1% of total murine lung cells (50). In contrast, the main 
ILC subset found in the lungs of humans are ILC3s, which contribute up to 60% of the total 
ILCs found in human lungs (51). ILC2s contribute to 30% of the total ILCs found in the lungs 
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of humans, while only 10% of total ILCs found in human lungs are group 1 ILCs. Although 
there are differences in the abundance of murine lung ILCs subsets compared to human lung 
ILCs subsets, ILCs in mice and humans are functionally very similar, therefore, murine lung 
ILCs are still valuable to research and use in preliminary studies (52). Furthermore, it is 
extremely difficult to access human lung tissue samples, therefore, murine models provide an 
alternative method to model mycobacterial infections. Although mice and humans develop 
similar immune responses against mycobacteria, it is important to note that there are differences 
regarding mycobacterial disease pathology (53). Humans infected with Mtb develop necrotic 
lesions, whereas, mice develop inflammatory but non-necrotic lesions (53). Despite 
pathological differences, mice are affordable, easy to house, and can be used to help model 
complex ILC-associated immunological responses to mycobacterial infections (54).  
 
Table 1. Overview of ILC subsets with regards to ILC subset subgroups, stimulating 
cytokines, effector cytokines, function and disease associations. Table adapted from Beamer and 
Wojno, 2018 (55). 
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Like T cells, ILCs have been observed to differentiate into different phenotypes in response to 
environmental signals. Human IFNγ-producing ILC1s have been discovered to differentiate 
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into IL-22-producing NKp44+ RORγt+ ILC3s in response to IL-2, IL1-β and IL-23 under in 
vitro conditions (52). Conversely, human NKp44+ ILC3s cultured in vitro with IL-2 and IL-12 
adopted an ILC1 like phenotype resulting in the downregulation of NKp44, RORγt and IL-22 
and an upregulation in IFNγ and T-bet.  
Murine studies have also identified that 33.4% of small intestinal NKp46- RORγt+ ILC3s also 
expressed T-bet+ (56). Interestingly, IL-23 levels in various parts of the small intestine 
correlated with the percentage of CCR6- RORγt+ T-bet+ ILCs, indicating that IL-23 may in part 
drive ILC3 differentiation to an ILC1 like phenotype (56). Overall, these results imply that the 
differentiation of ILC1s and ILC3s is reversible and that ILC plasticity depends highly on the 
external stimuli and the microenvironment that ILCs are located in.  
ILC2s may also exhibit plasticity, as GFP expressing ILC2s found in mice seven days after 
influenza A viral infection were discovered to downregulate GATA3 expression and upregulate 
the ILC1 associated receptors, IL-18Rα and IL-12Rβ2 (57). Interestingly, the expression of T-
bet was not detected in these differentiated ILC2s, indicating that T-bet may not be required for 
the upregulation of IL-18Rα and IL-12Rβ2. In the same study GATA3lo ILCs in mice 
accumulated in areas where there were high virus loads whereas, GATA3hi ILCs were located 
in high numbers in uninfected areas. These results suggest that upon influenza infection ILC2s 
in viral infected areas could exhibit plasticity and differentiate into ILC1 like cells due to the 
changing microenvironment (57). However, further studies need to be conducted to fully 
understand the mechanisms behind ILC2 plasticity and determine whether ILC2s can also 
differentiate into other ILC subsets during bacterial infections.  
These studies highlight the complex nature of ILC plasticity and indicate that ILCs are far more 
diverse than initially understood. ILC plasticity must therefore, be considered when 
categorising and identifying ILCs into subsets. Additionally, mycobacterial infections may also 
drive ILC plasticity resulting in enhanced effector responses.  
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1.5.6 Role of ILCs in mycobacterial infections 
The role ILCs play during Mtb infections have not been extensively studied. Early studies 
suggested that NK cells may aid in the generation of a protective immune response against Mtb 
infections as mice aerosolised with Mtb had a higher proportion of IFNγ-producing lung NK 
cells 14 days post-infection, compared to noninfected mice (58). However, depletion of NK 
cells in Mtb infected mice with anti asialo-GM-1 resulted in no difference in the number of Mtb 
colony forming units (CFU) found in the lungs compared to IgG isotype control treated mice 
infected with Mtb aerosols (58). These results suggest that there may be redundancies in the 
role immune cells play during Mtb infections or that immune cells other than NK cells are 
important in protecting against Mtb infections. This study also shows that although cells may 
respond to an infection, the presence of IFNγ-producing cells does not directly correlate to 
protection.  
ILC1s, but particularly ILC3s, have been shown to respond to mycobacterial infections. Four 
weeks post BCG intranasal (i.n.) inoculation, IFNγ-producing ILC1, ILC3 and NK cell 
populations accumulated in the lungs and lymph nodes of mice compared to naïve mice, 
however, the protective function of these cells was not shown (2). A more recent study of mice 
infected with aerosolised Mtb established that early accumulation of ILC3s in the lungs 
coincided with an accumulation of alveolar macrophages, followed by ILC2s; however, in this 
study there was no increase in the number of ILC1s (59). In addition, higher numbers of ILC1, 
ILC2 and ILC3s were found in lung tissues from TB patients compared to lung tissues from 
healthy controls, indicating that ILCs respond to mycobacterial infections (59). 
Additionally, ILCs may help control mycobacterial infections by recruiting phagocytic cells to 
the site of infection. RNA sequencing revealed that neutrophil recruiting chemokines, CXCL1 
and CXCL5, as well as monocyte recruiting chemokines CXCL17 and CCL2, were upregulated 
in sorted ILC3s isolated from lung tissues of TB patients compared to healthy controls; 
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however, it has not been investigated whether the upregulation of these chemokines enable 
recruitment of innate immune cells during Mtb infections (59).  
Murine studies have shown that ILC3s may be important for the generation of an effective 
immune response against Mtb. Specific deletion of ILC3s in Ahrf/f Rorγtcre mice resulted in an 
increase in the number of Mtb CFU present in the lungs of Ahrf/f Rorγtcre mice, decreased 
accumulation of alveolar macrophages and decreased formation of inducible bronchus alveolar 
lymphoid tissue, in comparison to Ahrf/f control mice (59). Collectively these results suggest 
that ILC3s may play a protective role in recruiting innate cells and modulating lymphoid follicle 
structures in the granulomas of mice infected with Mtb. Whether these ILC subsets can directly 
inhibit the growth of mycobacteria has not yet been investigated.  
1.6 Immunological Memory 
Immunological memory is the ability of an immune cell to ‘remember’ an encounter with a 
pathogen (60). Upon subsequent re-encounters with the same pathogen the secondary immune 
response is more effective and is faster acting than the immune response generated during the 
initial pathogen encounter. Immunological memory is therefore, critical for preventing disease 
and is the fundamental basis for vaccine development.  
Adaptive immunological memory often, but not always, correlates with protection from a 
pathogen or infection (61). Over the years BCG-induced memory CD4+ IFNγ-producing T cells 
have been attributed to Mtb protection; however, the evidence for this is weak and this 
attribution is likely due to the confusion between correlation and causation (61,62). 
Consequently, it is essential to understand this distinction when discussing immunological 
memory in the context of protection.  
1.6.1 Immunological memory dogma 
Immunological memory was thought to only be present in vertebrates with an adaptive immune 
system (63). However, innate immune cells, like adaptive immune cells, have also been shown 
 12 
to possess memory like properties, termed ‘trained immunity’ (64). Unlike adaptive memory 
responses that are pathogen-specific and are induced by gene rearrangements, trained immunity 
is induced by epigenetic changes which enhance the antimicrobial properties of innate immune 
cells allowing these cells to respond non-specifically to pathogens (64). However, trained 
memory responses often only last months compared to adaptive memory responses that last 
years (64).  
As a consequence of the immunological memory dogma the vast majority of TB research has 
only investigated the role memory CD4+ T cells play in regards to TB, whilst innate trained 
memory responses are poorly understood (2). CD4+ T cells are critical during primary Mtb 
infections (65); however, there is very little evidence in the literature to support the idea that 
memory CD4+ T cells are the main protective cell type induced by BCG vaccination (62).  
1.6.2 Trained immunity observed in ILC2s  
Murine ILC2s have been shown to exhibit trained immunity. Upon, i.n. administration of IL-
33, numbers of IL-5 and IL-13-producing murine ILC2 populations in the mediastinal lymph 
node (mLN) increased by more than 100 fold compared to naïve mice before contracting four 
months later to naïve mLN ILC2 levels (66). Additionally, when mice were pre-treated i.n. with 
an Aspergillus oryae serine protease and then challenged with an unrelated papain allergen, 3.5 
months later there was still a significantly higher proportion of IL-5 and IL-13-producing ILC2s 
in mice pre-treated with the serine protease in comparison to mice that were pre-treated with 
PBS (66). These results indicate that allergen pre-exposed ILC2s can become activated by 
unrelated allergens in a non-specific way, which is an indication that ILC2s can display ‘trained 
immunity’.  
1.6.3 BCG derived memory 
Although the BCG vaccine has been in clinical use for over a century, very little is known about 
which cell types and memory responses contribute to protection against Mtb following BCG 
vaccination (62). Kagina et al., conducted a study in the TB endemic country of South Africa, 
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where T cell responses of over 5000 infants who were vaccinated within 24 hours of birth were 
compared when the children reached two years of age. Results indicated that BCG induced 
CD4+ and CD8+ T cells did not correlate with protection against childhood TB (67). In contrast, 
a murine study concluded that BCG-induced T effector memory cell populations are strongly 
associated with protection due to the production of cytokines such as IFNγ and TNF-α (68). 
However, when BCG-vaccinated IFNγ KO mice and wild type mice were challenged with Mtb 
Erdnam both groups of mice exhibited similar reductions in bacterial burden compared to naïve 
IFNγ KO and wild type mice respectively (69). These conflicting results suggest that memory 
T cells might not be the main protective cells induced by BCG vaccination.  
BCG can induce non-specific protective effects in mice which may be due to the induction of 
a trained immune response of innate cells rather than highly specific memory T cells (70). BCG-
inoculated severe combined immunodeficient (SCID) mice (which lack T and B cells) have 
been found to have significantly higher survival rates compared to SCID saline control mice 
when challenged with a lethal dose of live Candida albicans (71). These results support the 
idea that BCG vaccination can induce a trained antigen non-specific innate immune response.  
Epigenetic reprograming is required to induce trained immunity in innate immune cells (64). 
Histone modifications in BCG-trained human monocytes can result in an increase in glycolysis 
and glutamine metabolism compared to untrained human monocytes (72). Additionally, three 
months after BCG vaccination levels of trimethylation of histone H3 at lysine 4 at cytokine 
promoters were significantly increased in circulating human monocytes, compared to levels 
before vaccination (71). Inhibition of histone modifications by a methyltransferase inhibitor 
significantly reduced TNFα production when trained monocytes were exposed to non-related 
pathogens. Consequently, BCG can induce epigenetic changes resulting in monocyte training 
and enhanced cytokine production. Whether, epigenetic changes occur in ILCs in response to 
BCG vaccination still remains unknown. 
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These studies emphasise the importance for ongoing research into the non-traditional area of 
trained innate memory. If the complexity behind BCG induced memory responses can fully be 
understood, a new vaccine could be designed to stimulate and promote these protective memory 
responses.  
1.7 Mycobacterial Growth Inhibition Assays (MGIA) 
A major hindrance in the progression of vaccine development against TB is our limited 
understanding surrounding which cell types and immune mechanisms are involved in 
protection against Mtb infections (73). While it is known that BCG can induce protection 
against TB in neonates, BCG-induced cell subsets that confer protection against Mtb are not 
well defined (10,11,62). It is difficult to identify protective cell types and cell mechanisms in 
vivo as the host immune response against Mtb is complex, involving both the innate and 
adaptive immune systems (1,73). However, in vitro MGIAs act as an alternative way to directly 
study vaccine induced protective cell types and immune mechanisms by modelling the in vivo 
immune response in a controlled in vitro system, whereby, vaccine induced immune cells 
infected with mycobacteria are cultured (73). Following culturing, cell cultures are plated onto 
agar. Immune cell inhibition of mycobacteria can be directly assessed by enumerating CFU. 
Directly assessing mycobacterial growth inhibition compared to measuring cytokine production 
may relate more directly with in vivo protection (73). Consequently, the development of in vitro 
growth inhibition assays can act as a useful method to study vaccine induced protective immune 
responses against Mtb. 
To date no MGIAs have been developed to assess the ability of ILCs to inhibit the growth of 
BCG. However, previous MGIAs have assessed the ability of splenocytes from BCG-
inoculated C57/BL6 mice compared to splenocytes from a naïve mouse to inhibit the growth 
of BCG. Splenocytes from immunised mice were discovered to significantly inhibit BCG 
growth, in comparison, to splenocytes from unimmunised mice (73,74). Additionally, other 
MGIAs have cultured Mtb Erdman infected murine bone marrow derived monocytes with 
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splenocytes from BCG Pasteur immunised and naïve C57BL/6 mice. Again, there was a 
significant 0.87 log10 reduction in the growth of mycobacteria cultured with splenocytes from 
BCG-vaccinated mice in comparison to mycobacteria cultured with splenocytes from naïve 
mice.  
These studies indicate that growth inhibition assays can be used to measure vaccine driven cell 
inhibition of mycobacterial growth. Consequently, the aim of this project was to use these 
models to establish an in vitro growth inhibition assay to assess the ability of ILCs to inhibit 
the growth of mycobacteria when co-cultured with splenocytes.  
1.8 Justification for Research 
The BCG vaccine is the only vaccine available to protect against TB (9). Although BCG 
provides protection against miliary and meningeal TB in neonates, BCG provides unreliable 
protection against the predominant form of TB; adult pulmonary TB (10,11). Therefore, a new 
efficacious vaccine against adult pulmonary TB is urgently required. Vaccine developments 
have been hindered as very little is known about which cell types and memory responses 
contribute to protection against mycobacterial infections following BCG vaccination (62). 
Current data has shown that BCG vaccination resulted in a significant increase in IFNγ-
producing ILC1s and ILC3s in the lungs of BCG-vaccinated mice compared to naïve mice (2) 
However, the protective efficacy of BCG induced ILCs against mycobacterial infections has 
never been assessed. It is theorised that IFNγ-producing ILCs will enhance the anti-
mycobacterial properties of phagocytic cells. Therefore, by determining whether ILCs can 
enhance phagocyte killing of mycobacteria this would indicate directly for the first time 
whether ILCs are able to elicit a protective immune response against mycobacteria. If BCG 
induced ILCs are shown to inhibit the growth of mycobacteria, in the future TB vaccines could 
be designed to try to enhance ILC derived protective immune responses.  
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1.9  Aim and Objectives 
The overarching aim of this honours project was to determine whether ILC subsets could 
enhance mycobacterial killing in vitro.  
1.9.1 Objective 1- To determine if surface marker expression is an accurate way to sort live 
ILCs subsets 
Currently, ILC subsets are identified by the expression of transcription factors, however, 
staining for transcription factor results in cell death due to the requirement of permeabilising 
the cell and nuclear membranes (37). Instead, antibodies against surface proteins and receptors 
can be used to help categorise and sort live ILC subsets since cells do not need to be 
permeabilised to stain for cell surface markers. However, unlike ILC subset transcription factor 
expression, ILC subset surface marker expression is not well established. To assess the ability 
of ILC subsets to enhance mycobacterial killing, my first objective was to develop a 
reproducible antibody panel that would allow me to identify and sort live lung ILCs subsets 
from BCG-inoculated mice based on cell surface receptors and proteins using the fluorescence-
activated cell sorting (FACS) Aria Fusion, thereby preserving their viability. If the expression 
of a cell surface marker aligned with the expression of the ILC subset specific transcription 
factor, it would indicate that this marker could confidently be used to identify an ILC subset.  
1.9.2 Objective 2- To establish an in vitro MGIA to compare the ability of ILC subsets to 
enhance mycobacterial killing  
The second objective of this project was to establish an in vitro mycobacterial growth inhibition 
assay protocol to assess whether sorted subsets of ILCs derived from BCG-inoculated mice, 
could enhance splenocyte killing of intracellular mycobacteria compared to BCG-infected 
splenocytes cultured alone. Growth inhibition was determined by lysing the cells four days after 
co-incubation and plating the suspensions onto agar to enumerate BCG CFU. 
1.10 Hypothesis 
ILC1 and ILC3 subsets were hypothesised to inhibit the growth of BCG as ILC1s and ILC3s 
have been discovered to not only produce effector cytokines and accumulate in the lungs of 
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mice infected with BCG or Mtb, but ILC3s have also been shown to upregulate chemokines 
involved in immune cell recruitment and modulate lymphoid follicle formation within the 
granulomas of mice infected with Mtb (2,59).  
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2 Materials and Methods  
2.1 Bacteria 
2.1.1 Bacterial preparation 
Cryotubes containing aliquots of previously titrated Mycobacterium bovis BCG Pasteur 1173P2 
and M. bovis BCG tandem dye (td) Tomato (Tokyo strain which was manipulated to express 
the pTEC27 plasmid) were stored at -80oC. Bacteria were thawed by placing the cryotubes in a 
37oC incubator for 5-10 minutes. Defrosted bacterial aliquots were sonicated for 10 seconds 
using a Bandelin Sonorex Ultrasonic Sonicator (Bandelin, Berlin, Germany) and were rested 
on ice for one minute. Sonication and resting steps were repeated a further two times to mitigate 
bacterial clumping. Cryotubes were then vortexed for 15 seconds before the bacteria was 
diluted for mouse administration.  
BCG Pasteur was diluted 1:4 in PBS/Tween-80 0.05% (Appendix 6.1.1) to 1.25x107 CFU/mL 
and 40 μl was i.n. administered to mice. For subcutaneous (s.c.) administration, BCG Pasteur 
was diluted 1:5 in PBS/Tween-80 0.05% to 1x107 CFU/mL and 100 μl was administered. 
Diluted BCG Pasteur suspensions were vortexed post-dilution and were stored at 4oC for a 
maximum time of two hours before use. 
2.2 Mice 
2.2.1 Animal ethics 
Mice were obtained from the Hercus Taeri Research Unit, University of Otago. Inbred specific 
pathogen free (negative for Helicobacter spp, Aspiculuris tetraptera, Syphacia obvelata, 
Minute Virus, Mouse Hepatitis Virus, Mouse Parvovirus, Mouse Norovirus, Rotavirus, 
Theiler`s Encephalomyelitis virus) C57BL/6 mice aged six weeks or older were used for all 
experiments. All mice were housed at the University of Otago, Microbiology, Animal Handling 
Facility in individually ventilated cages, under PC2 conditions. The mice were kept under a 12-
hour light/dark cycle and were provided with an open source of food and water. Experimental 
group sizes were based on previous ILC experiments (2).  
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All of the animal work was carried out in accordance with the Animal Welfare Act (1999) with 
approval from the University of Otago Animal Ethics Committee.  
2.2.2 Intranasal BCG Pasteur inoculation  
Mice were anesthetised by intraperitoneal (i.p.) injection containing 87 mg/kg ketamine and 2.6 
mg/kg xylazine (Phoenix Pharm Distributors Ltd., Auckland, New Zealand). Once adequately 
sedated, mice were placed in a supine position and 40 μl of BCG Pasteur containing 5x105 CFU 
was pipetted onto the nostrils of each mouse for inhalation. Mice were monitored until full 
consciousness and mobility was regained. The mice were also monitored and weighed daily for 
approximately three days until the weight of the mice stabilised.  
2.2.3 Subcutaneous BCG Pasteur inoculation  
Mice were injected s.c. with 100 μl of BCG Pasteur containing 1x106 CFU. The injection site 
of the mice was observed over the subsequent days to ensure that there was no sign of infection 
and that the mice remained healthy. 
2.3 Harvesting and Processing of Murine Tissues 
2.3.1 Aseptic technique  
All handling of animals and tissues was conducted aseptically in a class II biological safety 
cabinet.  
2.3.2 Mouse euthanasia and dissection 
Mice were euthanised by i.p. injection of a lethal dose (150mg/kg) of Pentobarbitone 300 
(Pentobarbital sodium; National Veterinary Supplies Ltd., Palmerston North, New Zealand). 
Mice were confirmed deceased by the cessation of breathing and absent pedal reflex. Ethanol-
sterilised scissors and forceps were used to dissect the mice. The lungs were flushed of red 
blood cells via injection of sterile 1x Phosphate Buffered Solution (1xPBS) (Appendix 6.1.1) 
into the left ventricle of the heart until the lungs changed colour from pink to white. Tissues 
(lungs or lungs and spleens) were dissected and stored in separate wells of a 12-well culture 
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plate containing 2 mL incomplete IMDM (iIMDM). The 12-well culture plate was placed in a 
chilly bin filled with ice for transport.  
2.3.3 Processing of tissue into single cell suspensions 
Using ethanol-sterilised forceps, the dissected lungs were transferred from the 2 mL iIMDM 
into a new well containing 2 mL of lung digestion buffer (Appendix 6.1.5) and were cut into 
2-3 mm segments using ethanol-sterilised scissors before being placed into a 37oC incubator 
with 5% CO2 for one hour. During the incubation period whole spleens were strained through 
the 70 μm cell strainers (Falcon a Corning Brand, New York, USA) using the end of a sterile 1 
mL syringe plunger. The strainer was then rinsed with 5 mL complete IMDM (cIMDM) or 
partial IMDM (pIMDM) for ILC surface marker fidelity tests and growth inhibition assay 
experiments respectively. The number of cells that remained attached to the structural tissue 
were not enumerated as the cell number would be negligible. In addition, the samples were 
strained and rinsed a further two times more times to increase the yield of single cells. After the 
one hour incubation period the lung segments were also strained through a 70 μm cell strainer. 
The single cell lung and splenocyte suspensions were centrifuged at 400xg for 8 minutes at 4oC. 
Following the centrifugation, the supernatant was discarded, and cells were resuspended in 500 
μl of cIMDM or pIMDM. 
The single cell lung suspensions were pooled together and further filtered through a 30 μm filter 
(MACS Miltenyi Biotec, Bergisch Gladbach, Germany) for use in growth inhibition assay 
experiments to remove any remaining structural tissue. The filter was rinsed twice with 1 mL 
of Easy Separation buffer (Appendix 6.1.3). A 50 μl sample of the pooled lung suspensions 
was taken for cell counting.  
2.3.4 Red blood cell lysis 
Splenocyte suspensions used in the growth inhibition assay experiments were resuspended in 1 
mL of Red Blood Cell Lysis Buffer Hybri-Max (Sigma-Aldrich, St. Louis, USA) and were left 
to incubate for one minute at room temperature. The suspension was diluted with 15 mL 
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pIMDM and centrifuged at 400xg for 8 minutes at 4oC. After centrifugation, the supernatant 
was discarded, and cells were resuspended in 5 mL of pIMDM. A 50 μl sample was taken from 
the splenocyte suspension for cell counting. 
2.3.5 Viable cell counting 
Cells were diluted either 1:10 or 1:5 in 0.1% trypan blue dye (Gibco, Life Technologies, Grand 
Island, USA). Cell numbers from all tissue samples were counted using trypan blue exclusion. 
Trypan blue stains dead cells blue while live cells with an intact membrane are unable to take 
up the dye and remain unstained. A 10 μl sample of the stained cell suspension was transferred 
to a hemocytometer (Boeckel & Co. GmbH, Hamberg, Germany) which was placed under a 
light microscope at 40x magnification. Live lymphocytes, that remained unstained, were 
counted and averaged across two quadrants. Lymphocyte numbers were calculated by 
multiplying the average lymphocyte number per quadrant by the dilution factor and 104 to give 
the cell number per mL. The cell number per mL was multiplied by the total cell suspension 
volume to determine the total number of lymphocytes.  
2.4 Cell Staining for Flow Cytometry 
Flow cytometry is a technique that is used to identify different subsets of cells in a sample via 
the use of fluorescently labelled antibodies against surface markers and intracellular 
transcription factors. When excited by a laser bean fluorescently labeled antibodies can emit 
light at specific wavelengths resulting in the ability to analyse and sort cells based on size, 
viability, and the expression of specific markers.  
All cells were incubated at 4oC and were shielded from light during each incubation step, unless 
otherwise stated. All centrifugations were performed in a Heraeus multifuge 4 KR centrifuge 
(Thermo Fisher Scientific, Waltham, MA, USA). 
2.4.1 FMO and unstained controls 
Fluorescence minus one (FMO) controls were created for each of the markers to accurately 
distinguish positive compared to negative signals, allowing the identification of ILCs. FMOs 
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were created by staining the cells with all of the antibodies against the surface markers and 
transcription factors from an antibody panel (Table 2-Table 4) except one antibody that 
represented the FMO. Unstained controls samples were not stained with any antibodies.  
2.4.2 FcγRII/III blockade 
To prevent non-specific binding of antibodies to Fc receptors, the FcγRII and FcγRIII which 
are expressed on lymphocytes were blocked by anti-CD32/16 antibody (clone 2.4G2, produced 
in-house). The Fc receptor block was diluted 1:100 in either FACS buffer (Appendix 6.1.2) or 
EasySepTM buffer for ILC surface marker fidelity tests and growth inhibition assay experiments 
respectively. The suspensions were incubated for 15 minutes to neutralise the Fc receptors, 
washed with 1 mL of FACS or EasySepTM buffer, and centrifuged at 400xg for 8 minutes.  
2.4.3 Lineage staining 
Lineage staining was used to negatively select for ILCs while unwanted lineage positive cells 
were targeted with biotinylated antibodies. Initially, 50 μl of the EasySepTM Mouse Pan-ILC 
Enrichment Cocktail (Stemcell Technologies, Vancouver, Canada) containing eight 
biotinylated antibodies against T cells (CD3e, TCR beta chain, TCR gamma/delta), B cell 
(CD19), macrophages (CD11b), dendritic cells (CD11c), erythrocytes (TER119) and 
neutrophils (CD11b, Gr-1) markers was added per mL of lung suspension. The cells were then 
incubated for five minutes at room temperature to enable lineage marker staining, before being 
washed with 500 μl of FACS or EasySepTM buffer for ILC surface marker fidelity tests and 
growth inhibition assay experiments respectively.  
2.4.4 Lineage depletion 
The EasySepTM Mouse Pan-ILC Enrichment Protocol (Stemcell Technologies) was followed 
to deplete lineage positive cells. Briefly, 75 μl of EasySepTM Streptavidin RapidSphere beads 
were added per mL of lung suspension. The suspension was left to incubate at room temperature 
for five minutes to enable lineage positive binding before the tube was topped up with 
EasySepTM buffer to a total volume of 2.5 mL. FACS tubes were placed into the EasySepTM 
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magnet for three minutes to allow for the lineage positive cells to magnetically adhere to the 
sides of the FACS tube. Post-incubation, the magnet and the sample tube were inverted for 
three seconds to transfer lineage negative cells into a new sterile FACS tube (labeled lineage-
depleted), leaving behind lineage positive cells. Lineage depletion was repeated on the cells in 
the lineage-depleted FACS tube to remove any lineage positive cells that remained in the 
lineage negative cell preparation after the initial lineage positive depletion. Following this, a 50 
μl sample of this suspension was taken to enumerate ILCs. The lineage positive depletion steps 
were omitted from the ILC panel experiments as lineage positive cells could be gated out based 
on the presence of lineage markers using Flow Jo software (Tree Star, Oregon, USA).  
2.4.5 Viability staining 
All FACS tubes containing cells were centrifuged at 400xg for four minutes, the supernatant 
discarded and resuspended in 500 μl of BD horizon FVS700 viability stain (Becton, Dickinson 
and Company. Franklin Lakes, New Jersey, USA) diluted 1:2000 in 1xPBS per 1x107 cells. 
The cells were incubated for 15 minutes at 4oC, after which time the cells were washed with a 
further 400 μl of 1x PBS and were centrifuged at 400xg for four minutes before the supernatant 
was discarded.  
2.4.6 Cell surface staining 
A master mix was prepared containing antibodies against ILC surface markers at dilutions 
determined by previous titration experiments (detailed in Table 3 and Table 4). Tissue 
samples, pre-depletion samples, the live dead FMO and intranuclear FMO controls were each 
resuspended in 500 μl of surface antibody master mix per 1x107 cells. Unstained cells were 
resuspended in 100 μl of FACS buffer. All tubes containing cells were incubated for 30 minutes 
at 4oC to stain for cell surface markers. Following the incubation period, the cells were washed 
with 500 μl of FACS buffer and centrifuged at 400xg for four minutes before being washed a 
second time with 1 mL of FACS buffer and centrifuged at 400xg for four minutes to wash away 
the residual antibody. 
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2.4.7 Intranuclear marker staining 
Intranuclear marker staining was only conducted in the ILC surface marker fidelity experiments 
and was not undertaken during the growth inhibition assay experiments as intranuclear staining 
requires permeabilisation of the cell membrane and the nuclear membrane, resulting in cell 
death.  
The BD Pharmingen Transcription Factor Buffer Set (Becton, Dickinson & Co.) was used to 
fix, and permeabilise the cells and increase the positive staining intensity for the intranuclear 
transcription factors T-bet, RORγt and GATA3.  
Concentrated Fixation/Permeabilisation buffer was diluted at a ratio of 1:4 in Transcription 
Factor Diluent buffer. FACS tubes containing cells were resuspended in 500 μl of this diluted 
Fix/Perm buffer. All FACS tubes containing cells were vortexed for three seconds and were 
incubated for 45 minutes at 4oC with gentle rocking. Post-incubation, the cells were washed 
with 500 μl of Perm/Wash buffer, which had been diluted 1:5 in distilled H2O (dH2O) and 
centrifuged at 350xg for six minutes. Cells were resuspended in 500 μl of the intranuclear 
master mix per 1x107 cells at dilutions determined by previous titration experiments (Table 2 
and Table 3) and incubated for 45 minutes at 4oC with gentle rocking. Cells were washed and 
centrifuged twice at 350xg for six minutes with 500 μl of Perm/Wash buffer, following 
resuspension in 100 μl of formalin (4% w/v formaldehyde; Sigma-Aldrich). Cells were 
incubated at room temperature for 10 minutes to allow for fixation, before the cells were washed 
with 900 μl of FACS buffer and pelleted at 350xg for six minutes. The supernatant was 
discarded, and the cells were resuspended in 200 μl of FACS buffer. FACS tubes were wrapped 
in aluminum foil and stored at 4oC for a maximum time of 48 hours before acquiring the data 



















Clone Lot Dilution Manufacturer  
Live Dead FVS700 - 7296869 1:2000 BD HorizonTM 
FcRγII, 
FcRγIII 
- 2.4G2 - 1:100 In-House 
CD45 APC-Cy7 30-F11 7138715 1:1000 BioLegend 
T-bet BV421 4B10 B246190 1:100 BioLegend 
GATA3 APC 16E10A23 B264084 1:100 BioLegend 
RORγt PE-CF594 Q31-378 8186548 1:100 BD HorizonTM 
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Table 3. Antibody panel for the ILC subset surface marker fidelity test  
 
Table 4. Antibody panel for total ILC sorts 
 




Clone Lot Dilution  Manufacturer  
Live Dead FVS700 - 7296869 1:2000 BD HorizonTM 
FcRγII, FcRγIII - 2.4G2 - 1:100 In-House 
CD45 APC-Cy7 30-F11 7138715 1:1000 BioLegend 
CD127 PE-Cy7 SB/199 7230868 1:100 BD 
PharmingenTM 
CD278 (ICOS) BV786 C398.4A B262906 1:100 BioLegend 
CD117 (c-Kit) BB700 2B8 8233960 1:200 BD HorizonTM 
CD122 (IL-2Rβ) PE TMβ1 B263878 1:200 BioLegend 
IL-23R BV650 O78-
1208 
9094690 1:100 BD OptiBuildTM 
T-bet BV421 4B10 B246190 1:100 BioLegend 
GATA3 AF647 L50-823 8124729 1:25 BioLegend 
RORγt PE-CF594 Q31-378 9073662 1:100 BD HorizonTM 
Streptavidin (Lineage ) PE-Cy5 - B202412 1:1000 BioLegend 
Specificity Fluorophore 
conjugate  
Clone Lot Dilution Manufacturer 
Live Dead FVS700 - 8218982 1:2000 BD HorizonTM 
FcRγII, FcRγIII - 2.4G2 - 1:100 In-House 
Lineage markers 




Biotin - - 1 Stemcell 
CD45 APC-Cy7 30-F11 7138715 1:1000 BioLegend 
CD127 PE-Cy7 SB/199 7230868 1:100 BD 
PharmingenTM 
Streptavidin (Lineage) PE-Cy5 - B202412 1:1000 BioLegend 
Antibody Fluorophore 
conjugate 
Clone Lot Dilution Manufacturer 
F4/80 PE/Cy5 BM8 B19821 1:800 BioLegend 
 27 
2.4.8 Compensation controls  
Spillover is caused by the overlap of emissions spectra from different fluorochromes. To correct 
for spillover, single stained compensation controls were made and values for spillover were 
determined by FACSDiva software (Becton, Dickinson & Co, Biosciences). 
Compensation controls for cell surface antibodies were prepared by adding one drop of 
OneComp eBeads (Thermo Fisher Scientific, Waltham, Massachusetts, USA), 1 μl of the 
respective antibody and 100 μl of FACS buffer to a FACS tube before being left to incubate for 
15 minutes at 4oC. Beads were washed with 500 μl of FACS buffer and the tubes were 
centrifuged at 400xg for four minutes. Following the centrifugation, the supernatant was 
discarded, and cells were resuspended in 100 μl of FACS buffer.  
Live dead compensation controls were made using ethanol fixed cells instead of beads. The 
fixed cells were incubated for 15 minutes with 1 μl of BD horizon FVS700 and 100 μl of 1xPBS 
to allow for positive staining of dead cells.  
A lineage compensation control was prepared by the addition of 1 μl of the F4/80 antibody 
(Table 5) conjugated to PE-Cy5 and one drop of OneComp eBeads to 100 μl of FACS buffer. 
The F4/80 antibody was used instead of streptavidin conjugated to PE-Cy5, as streptavidin is 
only able to bind to biotin and is therefore, unable to bind to the beads.  
Intranuclear compensation controls were prepared by adding one drop of OneComp eBeads and 
1 μl of the respective intranuclear antibody to 100 μl of Perm/Wash buffer. The intranuclear 
compensation controls were then incubated on a rocker for 45 minutes at 4oC. Following the 
incubation period, the beads were washed twice with 500 μl of Perm/Wash buffer before being 
formalin fixed, centrifuged and resuspended in 200 μl of FACS buffer.  
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2.5 Flow Cytometry Acquisition and Analysis 
2.5.1 Data acquisition and analysis  
Acquisition of events was performed on a BD LSR-Fortessa using FacsDIVA (version 8.0, 
BD). A minimum of 1x106 events was recorded for each sample and a minimum of 500,000 
events was recorded for each FMO and unstained control. Data was exported as Flow cytometry 
standard 3.1 files and analysed using FlowJo (version 10.6.1, Tree Star, Ashland, OR, USA) 
software. Graphs were created using GraphPad Prism version 8.2 software (GraphPad Software 
Inc., California, USA).  
2.5.2 Statistical analysis 
All statistical analyses were carried out using GraphPad Prism version 8.2 software. The Man-
Whitney U test followed by Dunn’s multiple comparisons test were used to compare differences 
in the medians of multiple groups due to the non-parametric nature of the data 
2.6 In vitro MGIA 
2.6.1 Set up of the 48 well plate 
Lymphocytes from lung derived cell suspensions (lineage positive cells from an BCG Pasteur 
i.n. inoculated mouse, total lung cells (TLC) from a naïve mouse) and spleen suspensions 
(splenocytes from a naïve mouse, splenocytes from an BCG Pasteur i.n. inoculated mouse and 
splenocytes from a BCG Pasteur s.c. vaccinated mouse) were enumerated using a 
hemocytometer and trypan blue exclusion counting. Cell suspensions were diluted with 
pIMDM to prepare a total volume that could be divided across the wells of a 48 well plate. The 
lung-derived cell suspensions were vortexed before 6.1 - 6.3x103 and 1.23 - 1.26x104 lineage 
positive cells, TLC and sorted ILCs were pipetted into separate wells of a 48 well plate (Table 
6 and Table 7). The splenocyte suspensions were also vortexed before 5x105 and 1x106 of the 
naïve splenocytes were pipetted into the same wells as the lung derived cells. The two different 
numbers of splenocytes (5x105 and 1x106) and lung cells (6.1 - 6.3x103 and 1.23 - 1.26x104) 
were used to determine if the ratio of lung cells to splenocytes affected the ability of these cells 
to inhibit the growth of BCG tdTomato. Separate control wells were also made by pipetting 
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5x105 and 1x106 splenocytes from a BCG Pasteur s.c. vaccinated mouse, naïve splenocytes or 
splenocytes from an BCG Pasteur i.n. inoculated mouse into separate wells. Finally, all of the 
wells were infected with BCG tdTomato at a multiplicity of infection (MOI) 1:3450 (BCG : 
splenocytes). This MOI was used as a previous study was able to determine a significant 
difference in the ability of splenocytes derived from BCG-vaccinated mice to inhibit the growth 
of BCG Pasteur Aeras, compared to splenocytes derived from saline treated mice at MOIs 
ranging from 1:1500 to 1:50,000 (75). The wells were then filled up to a volume of to 975 μl 
with pIMDM and pipetted up and down 3-4 times to ensure that there was even distribution of 
the BCG tdTomato. The wells around the perimeter of the plate that were not used were filled 
with iIMDM to act as a barrier and prevent the wells on the inside from drying out. The 48 well 
plates were then incubated at 37oC with 5% CO2 for 96 hours and were examined once a day 






Table 6: Sample and control groups from first and second in vitro MGIAs. In the first growth inhibition assay experiment each lung suspension well 
contained 6.3x103 or 1.26x104 lung cells and all sample and control wells were in triplicate. In the second growth inhibition assay all sample ILC wells 
were in duplicate due to insufficient numbers of sorted total ILCs, whereas all other wells were in triplicate. All lung suspension wells during the second 






Number of cells added 
Sample  6x103 total sorted ILCs from 4-week 
post BCG i.n. inoculated mouse  
5x105 splenocytes from a naïve mouse  
6x103 total sorted ILCs from 4-week 
post BCG i.n. inoculated mouse 
1x106 splenocytes from a naïve mouse 
1x104 total sorted ILCs from 4-week 
post BCG i.n. inoculated mouse 
5x105 splenocytes from a naïve mouse  
Positive Control 6x103 lineage positive cells from an 
i.n. inoculated mouse 
5x105 splenocytes from a naïve mouse  
6x103 lineage positive cells from an 
i.n. inoculated mouse 
1x106 splenocytes from a naïve mouse 
1x104 lineage positive cells from an 
i.n. inoculated mouse 
5x105 splenocytes from a naïve mouse  
Positive Control  5x105 splenocytes from a 4-week post 
BCG i.n. inoculated mouse  
1x106 splenocytes 4-week post BCG 
i.n. inoculated mouse  
 
Negative Control 6x103 TLC from a naïve mouse 
5x105 splenocytes from a naïve mouse  
6x103 TLC from a naïve mouse 
1x106 splenocytes from a naïve mouse 
1x104 TLC from a naïve mouse 




Table 7: Sample and control groups from the third and fourth in vitro MGIAs with additional controls. Sample ILC wells were in duplicate due to 
insufficient numbers of sorted total ILCs, however, all other wells were in quadruplicate. All of the sample and control wells were infected with BCG 
tdTomato at a multiplicity of infection of 1:3450 (BCG tdTomato : splenocytes).  
Control/Sample 
Groups 
Number of cells added 
Sample  6x103 total sorted ILCs from 4-week 
post BCG i.n. inoculated mouse  
5x105 splenocytes from a naïve mouse  
6x103 total sorted ILCs from 4-week 
post BCG i.n. inoculated mouse 
1x106 splenocytes from a naïve mouse 
1x104 total sorted ILCs from 4-week 
post BCG i.n. inoculated mouse 
5x105 splenocytes from a naïve mouse  
Positive Control 6x103 lineage positive cells from an 
i.n. inoculated mouse 
5x105 splenocytes from a naïve mouse  
6x103 lineage positive cells from an 
i.n. inoculated mouse 
1x106 splenocytes from a naïve mouse 
1x104 lineage positive cells from an 
i.n. inoculated mouse 
5x105 splenocytes from a naïve mouse  
Positive Control  5x105 splenocytes from a 4-week post 
BCG i.n. inoculated mouse  
1x106 splenocytes 4-week post BCG 
i.n. inoculated mouse  
 
Positive Control 5x105 splenocytes from a 4-week post 
BCG s.c. inoculated mouse 
1x106 splenocytes 4-week post BCG 
s.c. inoculated mouse 
 
Negative Control 6x103 TLC from a naïve mouse 
5x105 splenocytes from a naïve mouse  
6x103 TLC from a naïve mouse 
1x106 splenocytes from a naïve mouse 
1x104 TLC from a naïve mouse 
5x105 splenocytes from a naïve mouse  
Negative Control 5x105 splenocytes from a naïve mouse 1x106 splenocytes from a naïve mouse  
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2.6.2 Plating and counting BCG tdTomato colonies 
Following the 96 hour incubation, under aseptic conditions, the supernatant containing the non-
adherent cells from each well were pipetted into separate sterile 2 mL microcentrifuge tubes. 
The nonadherent cells were then pelleted at 13,400xg for 10 minutes. During this time, 975 μl 
of dH20/Tween-80 0.05% was added to the tissue culture wells to lyse any adherent cells. After 
centrifugation the supernatant from the 2 mL microcentrifuge tubes was discarded. The 
dH20/Tween-80 0.05% suspension in each of the wells was pipetted up and down 3-4 times 
whilst the bottom of the plate was scratched and agitated with the pipette tip to dislodge 
adherent cells. Microcentrifuge tubes containing the pelleted cells were vortexed to resuspend 
the cells. Finally, the dH20/Tween-80 0.05% suspensions were pipetted into the corresponding 
microcentrifuge tubes containing the resuspended cells. The tubes were left to incubate for five 
minutes to allow for the lysis of the cells. All microcentrifuge tubes were then vortexed for 
three one minute intervals.  
Numbers of BCG tdTomato CFU was determined by spreading 200 μl of the bacterial 
suspension directly onto 7H11 agar plates supplemented with Oleic acid Albumin Dextrose 
Catalase (OADC) (Appendix 6.1.6).  The bacterial suspension was also serially diluted 10 fold 
in dH20/Tween-80 0.05% and 10 μl of each dilution (1/10, 1/100, 1/100) was spot plated onto 
another 7H11 agar plate (Appendix 6.1.6) supplemented with OADC. Plates were incubated at 
37oC for 2-3 weeks before individual BCG tdTomato colonies were counted and recorded. BCG 
tdTomato colonies could be distinguished from BCG Pasteur colonies by colony colour. BCG 
tdTomato colonies contain a plasmid that encodes the red reporter gene; tdTomato, resulting in 





It is well established that flow cytometry and fluorescently labeled antibodies against the 
transcription factors: T-bet, GATA3 and RORγt can be used to broadly identify total ILCs into 
subsets (37). Transcription factors can remain in the nucleus or can localise to the cytoplasm 
after transcription. The cell and nuclear membranes, therefore, both need to be permeabilised 
to allow fluorescently labeled antibodies against the transcription factors to successfully enter 
the nucleus and cytoplasm for fluorescence-based cell sorting; however, permeabilisation 
results in the death of the cell. To compare the ability of ILC1 and ILC3 subsets to enhance 
mycobacterial killing, live ILC subsets needed to be sorted.  
Live ILC subsets can be identified and sorted based on the expression of surface proteins and 
receptors since antibody staining against surface markers does not require cell permeabilisation. 
However, unlike the canonical ILC transcription factors, ILC subset specific surface markers 
are not well established and there is wide heterogeneity in the literature regarding the use of 
surface markers to identify and sort live ILCs into subsets.  
Therefore, the first objective of this project was to determine whether surface protein and 
receptor expression was a suitable means to identify live ILC subsets. If the ILC subset specific 
surface marker expression aligned with the detection of the canonical ILC subset transcription 
factors, this would indicate that the surface proteins or receptors could be used confidently to 
help identify live ILC subsets. Live, sorted ILCs subsets would then be used to establish an in 
vitro growth inhibition assay to determine whether BCG vaccine-induced ILC1s and ILC3s 
could enhance mycobacterial killing.  
Before any experiments could be undertaken to assess the fidelity of the ILC surface markers, 
transcription factor staining was first optimised.  
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3.1 Optimisation of GATA3 transcription factor staining 
3.1.1 Transcription factor antibody panel test 
To ensure optimal antibody labeling of the transcription factors T-bet, GATA3 and RORγt, a 
transcription factor antibody panel test was conducted. Lung cells derived from a naïve mouse 
were stained with a viability dye and an antibody against the lymphocyte cell surface receptor 
CD45 (Table 2). Cells were then fixed and permeabilised before cells were stained with 
antibodies against T-bet, GATA3 and RORγt (Table 2). Total lymphocytes were used instead 
of ILCs to assess transcription factor staining efficacy as total lymphocytes are found in high 
abundance in murine lungs in comparison to ILCs and are therefore, easier to isolate and use 
during antibody titrations and optimisations of transcription factor staining protocols (50). 
Figure 1. Transcription factor antibody panel test revealed that GATA3 APC staining failed. 
Lung cells derived from a naïve C57BL/6 mouse were stained with a viability dye and antibodies 
against CD45 and transcription factors: GATA3, T-bet and RORγt. Events were acquired using a 
BD LSR Fortessa. Live, fixed lymphocytes were gated on, followed by CD45+ cells. Cells were 
then gated on the expression of T-bet, GATA3 and RORγt based on unstained and FMO controls. 
Biaxial flow plots show T-bet BV421 (A) RORγt PE-CF594 (B) and GATA3 APC staining (C).  
 
Anti-T-bet monoclonal antibody (mAb) conjugated to the fluorophore brilliant violet (BV)421 
and anti-RORγt mAb conjugated to phycoerythrin (PE)-CF594 staining of live, fixed CD45+ 
murine lymphocytes was successful, as indicated by clear positively stained cell populations 
















T-bet BV421 GATA3 APC RORγt PE-CF594 
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not express high levels of T-bet, GATA3 or RORγt as these cells had not previously been 
exposed to pathogens, no live, fixed CD45+ murine lymphocytes were positive for anti-GATA3 
mAb conjugated allophycocyanin (APC), indicating that GATA3 staining was unsuccessful 
(Figure 1C).  
3.1.2 GATA3 staining of 4-week post BCG Pasteur intranasally inoculated mouse 
GATA3 positive cell populations have previously been identified in the lungs of mice infected 
with mycobacteria (76,77). Accordingly, lung cells derived from a 4-week post BCG i.n. 
inoculated mouse were stained with the anti-GATA3 APC mAb. Despite the active BCG 
infection, staining of murine lung cells with anti-GATA3 mAb was again unsuccessful. Dot 
plots show that there were <0.05% live, fixed CD45+ GATA3+ lymphocytes identified in the 
sample (Figure 2B).
Figure 2. GATA3 staining of lungs cells from a 4-week post BCG Pasteur i.n. inoculated 
mouse was unsuccessful. Lung cells derived from a 4-week post BCG i.n. inoculated C57/BL6 
mouse were stained with a viability dye and antibodies against CD45, CD127, CD122, CD278, IL-
23R, CD117, lineage markers and transcription factors: GATA3, T-bet, and RORγt. Events were 
acquired using the BD LSR Fortessa. Live, fixed lymphocytes were gated on, followed by CD45+ 
cells. Cells were then gated on the expression of GATA3 based on unstained and FMO controls. 
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3.1.3 Fluorophore size may have contributed to unsuccessful GATA3 APC staining of murine 
lung cells 
It was hypothesised that the fluorophore size might have impeded intranuclear staining of 
GATA3 as the larger the fluorophore the more difficult it is for the mAb to efficiently penetrate 
through the cell and nuclear membranes, resulting in unsuccessful staining. One of the largest 
fluorophores is APC which is a naturally fluorescent protein with a molecular weight of 105,000 
Daltons (78). Alexa Fluor (AF)647 is a fluorescent dye, which has a considerably smaller 
molecular weight of 1464 Daltons, compared to APC (79). With a considerably smaller 
molecular weight it was theorised that the anti-GATA3 mAb conjugated to AF647 would be 
able to penetrate through the nuclear membrane with a higher efficacy, resulting in enhanced 
GATA3 staining efficacy compared to the anti-GATA3 mAb conjugated to APC.  
Figure 3. GATA3 staining of lung cells from a naïve mouse was successful when anti-GATA3 
mAb was conjugated to the AF647 fluorophore. Lung cells derived from a naïve C57BL/6 mouse 
were single stained with anti-GATA3 AF647 mAb. Events were acquired using a BD LSR Fortessa. 
Cells gated on time, followed by FSC, and SSC singlet gates. Lymphocytes were gated on followed 
by GATA3+ cells. Gates were set based on the unstained control. Biaxial dot plots show GATA3 
AF647 staining of the unstained control A, compared to the single stained sample B. 
 
As hypothesised, GATA3 staining efficacy of lung cells derived from a naïve mouse was 
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previous experiments that had used anti-GATA3 mAb conjugated to APC (Figure 1C and 
Figure 3B). These results indicate that the fluorophore size may have contributed to 
intranuclear staining efficacy. Consequently, the anti-GATA3 mAb conjugated to AF647 was 
used in future experiments.  
3.2 Determining if surface marker expression can accurately be 
used to identify live ILC subsets 
To be able to compare the ability of different ILC subsets to enhance mycobacterial killing, it 
was important to develop an antibody panel that could help categorise and sort live ILCs into 
subsets based on the expression of cell surface proteins and receptors.  
A comprehensive literature search was conducted to identify surface markers that might 
accurately differentiate total ILCs into subsets (Table 8). All ILC subsets are negative for 
lineage markers present on T cells (CD3e, TCR beta chain, TCR gamma/delta), B cells (CD19), 
macrophages (CD11b), DC (CD11c), erythrocytes (TER119) and neutrophils (CD11b, Gr-1) 
(2). Leukocytes including ILCs, express protein tyrosine phosphatase receptor type C (PTPRC), 
otherwise known as CD45 (80). CD45 is required for leukocyte activation and development 
and therefore, CD45 was chosen to positively identify ILCs in the lineage negative population 
(80). In addition to CD45, CD127 which forms the IL-7R alpha chain, was also selected to 
positively identify ILCs, since most ILCs express CD127 (81). CD127 plays an important role 
in development and maintenance of ILCs (82). 
To identify specific subsets of ILCs, antibodies against additional cell surface receptors and 
proteins were selected. IL-15 is a cytokine that is critical for the survival and development of 
group 1 ILCs (83). IL-15 can bind to the IL-15 lymphocyte surface receptor which consists of 
an α, β and γ subunit (84). The β subunit, also known as CD122, is only expressed on ILC1s, 
therefore, CD122 was selected as the surface receptor to identify ILC1s (37).  
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Since ILC2s are the only ILC subset that have been shown to express CD278 (ICOS; inducible 
T-cell costimulator), the CD278 marker was selected to identify ILC2s (37). ICOS and ICOS 
ligand interactions promote ILC2 survival and cytokine production (85).  
IL-23R was chosen as a surface receptor to positively identify ILC3s, since ILC3s are the only 
ILC subset that have been shown to express IL-23R (37). IL-23 can also promote the 
differentiation of ILC1s to ILC3s resulting in the upregulation of RORγt, indicating that the 
regulation of IL-23R and RORγt expression may be linked (52).  
In addition to IL-23R, CD117 (c-KIT) was also selected to identify ILC3s since LTi cells have 
been shown to express high levels of CD117 (37). Some studies have indicated that certain 
ILC2 populations also express CD117; however, ILC2s should still be distinguishable through 
the expression of CD278 (37). Although the role of CD117 in the context of ILCs has not been 
well established CD117+ ILCs have been shown to upregulate micro ribonucleic acids that are 
involved in inhibiting cell growth and therefore, promoting cell survival (86).
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Table 8. Identification of murine ILC subsets based on the expression of transcription factors, 
surface proteins and markers. A.LTi cells express CD117, NCR negative and positive ILC3s have 
weak expression for IL-17. B. ExILC3s can express T-bet, whereas, conventional ILC3s do not 
express T-bet. Referenced studies predominantly assessed marker expression on murine lung ILCs, 
however, murine ILCs derived from the liver, small intestine, skin, uterus, salivary glands, bone 
marrow and lymph nodes were also assessed.  
Despite undertaking a comprehensive literature search, there was wide heterogeneity between 
studies with respect to use of surface proteins and receptors to identify ILCs subsets. Therefore, 
an ILC subset surface marker fidelity test was undertaken to determine if the chosen surface 
makers (CD122, CD278, IL-23R and CD117) aligned with the expression of the canonical ILC 
subset transcription factors (T-bet, GATA3, RORγt). Alignment of surface marker and 
transcription factor expression would indicate that the surface markers could be used to 
confidently identify ILC subsets. 
The ILC subset surface marker fidelity test was conducted on lung cells derived from a 4-week 
post BCG i.n. inoculated mouse as i.n. administration has been shown to significantly enhance 
the effector functions of ILCs (2). Additionally, numbers of murine lung ILC1, ILC2 and ILC3s 
have previously been discovered to peak 4-weeks after BCG-inoculation (2). Consequently, the 
yield of total ILCs isolated from the lungs of 4-week post BCG i.n. inoculated mice would be 
 Markers ILC1 ILC2 ILC3 
Lineage  CD3e, CD11b, 
CD11c, CD19, Gr-
1, TER119, TCR β  
chain, TCRγ/δ 
- (2) - (2) - (2) 
Surface Markers CD45 (PTPRC) + (37) + (37) + (37) 
CD127 (IL-7Rα) + (2,37,81) + (2,37,81) + (2,37,81) 
CD122 (IL-2Rβ) + (37) - (37) - (37) 
CD278 (ICOS) - (37) + (37,87) - (37) 
CD117 (c-KIT) -(37) +/- (40) +A. (37) 
IL-23R -(2,37) - (2,37) + (2,37) 
Transcription 
Factors 
T-bet (TBX21) + (37) - (37) +/- B. (37) 
GATA3 - (37)  + (37,40) - (37) 
RORγt - (37) - (37) + (37) 
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higher than if ILCs were sourced from 1-week or 12-week BCG i.n. inoculated mice (2). Murine 
lung cells were stained with a viability dye, before being stained with antibodies against lineage 
markers, surface markers and the transcription factors (see Table 3). Events were acquired 
using a BD LSR Fortessa flow cytometer and analysed using Flow Jo software. 
3.2.1 CD117 aligned with GATA3 expression rather than RORγt expression 
 CD117 was the only surface protein selected that had previously been discovered to be 
expressed by more than one subset of ILCs, namely, ILC3s and some ILC2s (37,86). It was 
important to first determine whether ILC CD117 expression aligned with the canonical ILC2 
transcription factor, GATA3 or the canonical ILC3 transcription factor, RORγt, as this would 
indicate whether CD117 was a good marker to identify ILC3s from total ILCs. The percentage 
of live, fixed lineage-, CD45+, CD127+ CD117+ ILCs from the lungs of a BCG i.n. inoculated 
mouse expressing GATA3 and RORγt was assessed.  
Figure 4. CD117 failed to identify ILC3s. Lung cells derived from a 4-week post BCG i.n. 
inoculated mouse were stained with a viability dye and antibodies against CD45, CD127, CD122, 
CD117, CD278, IL-23R, T-bet, RORγt, IL-23R. Cells gated on time, followed by FSC, and SSC 
singlet gates. Lymphocytes were then gated on, followed by live, fixed CD45+ cells, lineage- cells, 
and CD127+ cells. CD117+ cells were then gated on before GATA3 and RORγt expression was 
analysed. Data representative of two experiments, n=1. 
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Surprisingly, 51.2% of lineage-, CD45+, CD127+ CD117+ murine lung ILCs expressed the ILC2 
transcription factor, GATA3 (Figure 4). In comparison, only 2.39% of lineage-, CD45+, 
CD127+ CD117+ murine lung ILCs expressed the ILC3 transcription factor, RORγt. These 
results imply that CD117 could not be used to distinguish murine ILC3s from other ILC subsets. 
3.2.2 Finalised gating strategy to identify of ILC subsets by surface markers 
Since CD117 expression did not align with the canonical ILC3 transcription factor, RORγt, the 
gating strategy used to identify ILC subsets was amended. The finalised gating strategy to 
identify ILCs subsets is depicted in Figure 5 and described below. 
A time gate was initially used to gate out any areas of time where there was an unstable flow 
of cells (Figure 5A). Following the time gate, two singlet gates were used to exclude any 
doublets or debris from further analysis (Figure 5B, 5C). Doublets occur when two or more 
particles pass through the interrogation point close together and are recorded as one event. 
Doublets can be gated out as doublets typically have a larger area relative to height, while the 
area of a single cells is proportional to the height of that cell. Lymphocytes could then be gated 
on while other cells and debris could be gated out as lymphocytes are small and non-granular 
(Figure 5D). Live cells that have an intact cell membrane cannot take up the viability dye, 
therefore, live, fixed cells stained negative. Live, fixed CD45+ leukocytes were then gated on 
(Figure 5E). Staining for lineage markers allowed total ILCs to be distinguished from lineage 
positive cells: T-cells, B-cells, macrophages, neutrophils, DC, and erythrocytes (Figure 5F). 
CD127+, lineage negative total ILCs were then gated on (Figure 5G). ILC1s were identified as 
CD122+ CD278- cells, and CD122- CD278+ cells were categorised as ILC2s (Figure 5H). 
ILC3s were identified as CD122- CD278- and were now further gated solely on their expression 
of IL-23R (Figure 5I). All ILC subsets were then gated on the expression of the ILC 



















Figure 5. Representative biaxial dot plots depicting the gating strategy used to identify ILC 
subsets from the lungs of a 4-week post BCG Pasteur i.n. inoculated C57BL/6 mouse. Events were 
acquired using a BD LSR Fortessa. Initially cells were gated on time (A), followed by FSC (B), and 
SSC singlet gates (C). Lymphocytes were then gated on (D), followed by live, fixed CD45+ cells (E), 
lineage- cells (F), and CD127+ cells (G). ILC1s were identified as CD122+ CD278- cells (H), ILC2s 
were identified as CD122-, CD278+ cells (H), and ILC3s were identified as CD122- CD278- cells (H) 
and were further gated on IL-23R+ expression (I). ILC1s (J-L) ILC2s (M-O) and ILC3s (P-R) were 
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Figure 6. CD122, CD278 and IL-23R surface marker expression did not align with the 
corresponding canonical ILC subset specific transcription factor expression. Lung cells were 
derived from a BCG i.n. inoculated C57BL/6 mouse. Live, fixed cells were gated on, followed by 
lymphocytes, and lineage- cells. CD127+, CD45+ cells were then gated on. ILC1s were identified as 
being CD122+ CD278-, ILC2s were identified as CD122-, CD278+, and ILC3s were identified as 
being CD122- CD278- and were further gated on IL-23R+ expression. ILC1s, ILC2s, and ILC3s 
were also gated on T-bet, GATA3 and RORγt expression using Boolean gating. Pie graphs represent 
the proportion of CD122+ ILCs, CD278+ ILCs and IL-23R+ ILCs that expressed the transcription 
factor: T-bet, GATA3, and RORγt. Data representative of two experiments, n=1. 
 
3.2.3 Low fidelity of all ILC subset surface markers in regards to transcription factor 
expression 
CD122 has previously been used as a marker to distinguish group 1 ILCs from other ILC 
subsets (37,88). Unexpectedly, results from the ILC subset surface marker fidelity test indicated 
that 49% of CD122+ CD278- IL-23R- ILCs did not express any of the canonical transcription 
factors; T-bet, GATA3, and RORγt (Figure 6). Alternatively, only 53% of lineage- CD45+ T-
bet+ ILCs expressed CD122 (data not shown), implying that CD122 expression weakly aligned 
with T-bet expression. There was also transcriptional heterogeneity within CD122+ ILCs 
populations as 1.7% of CD122+ ILCs co-expressed T-bet and RORγt and 1.9% solely expressed 
RORγt+ (Figure 6). These results imply that CD122 expression did not strongly align with T-
bet expression and that an alternative surface marker should be used to categorise group 1 ILCs.  
CD278 was chosen as the surface marker to distinguish ILC2s from ILC1 and ILC3 
populations. Similar to the CD122+ CD278- IL-23R- ILC population, 33% of CD122- CD278+ 
CD278
+
 ILCs CD122+ ILCs IL-23R+ ILCs 
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IL-23R- ILCs did not express any of the ILC transcription factors and merely 36.6% of CD122- 
CD278+ IL-23R- ILCs expressed the ILC2 transcription factor; GATA3 (Figure 6). Only 10% 
of lineage- CD45+ GATA3+ ILCs expressed CD278 (data not shown), implying that CD278 
expression did not align with GATA3 expression. There was also heterogeneity within the 
CD122- CD278+ IL-23R- ILC population as 16% of CD122- CD278+ IL-23R- ILCs, expressed 
the canonical ILC3 transcription factor RORγt; furthermore, 11.7% expressed both GATA3 
and RORγt and 2.6% solely expressed T-bet. These results imply that CD278 did not align with 
the ILC2 transcription factor GATA3 and that in the future an alternative surface marker should 
be used to identify ILC2s.  
IL-23R expression has previously been used to identify group 3 ILCs, however, 0% of CD122- 
CD278- IL-23R+ ILCs expressed the ILC3 transcription factor, RORγt (Figure 6) (2). 
Additionally, 35.7% of all CD122- CD278- IL-23R+ ILCs did not express T-bet, GATA3 or 
RORγt, while 35.7% of CD122- CD278- IL-23R+ cells expressed T-bet, 21.4% solely expressed 
GATA3 and 7.14% co-expressed both GATA3 and RORγt. Only 1.1% of lineage- CD45+ 
RORγt+ ILCs expressed IL-23R (data not shown), indicating that nearly 99% of RORγt+ ILC3s 
could not be identified using the IL-23R surface marker. This implies that IL-23R should not 
be used to identify murine ILC3s and that another surface marker that aligns with RORγt 
expression should instead be used to identify group 3 ILCs.  
3.2.4 Low number of ILC1, ILC2 and ILC3s were identified by current ILC subset surface 
markers……….. 
As CD122, CD278 and IL-23R surface markers did not align with the respective ILC subset 
transcription factor expression; T-bet, GATA3 and RORγt, only low numbers of ILC1s, ILC2s 
and ILC3s could be identified from murine lung cells. Before gating there was 2x107 live 
leukocytes present in the lungs of a BCG i.n. inoculated mouse (Figure 6). A total of 42,300 
live, fixed CD45+, CD127+, lineage- total ILCs were identified; however, nearly 27,000 of these 
ILCs did not express CD122, CD278 or IL-23R and therefore, could not be categorised into 
ILC subsets. Of the 10,808 CD122+ ILCs, only 4939 expressed T-bet. Similarly, 3372 ILCs 
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expressed CD278, however, of these cells only 1456 expressed GATA3. Finally, of the 364 IL-
23R+ ILCs none of these cells expressed RORγt (Figure 7). The low numbers of IL-23R+ ILCs 
were concerning as previous studies have identified up to 1x104 ILC3s in murine lungs 4-weeks 
after i.n. BCG inoculation (2). 
Figure 7. Low ILC subset numbers were identified in the lungs of a BCG i.n. inoculated 
C57BL/6 mouse. Lung cells were derived from a BCG i.n. inoculated C57BL/6 mouse. Live, fixed 
cells were gated on, followed by lymphocytes, and lineage- cells. CD127+, CD45+ cells were then 
gated on. ILC1s were identified as being CD122+ CD278-, ILC2s were identified as CD122-, 
CD278+, and ILC3s were identified as CD122- and CD278- and were further gated on IL-23R+ 
expression. ILC1s, ILC2s, and ILC3s were also gated on T-bet, GATA3 and RORγt expression 
using Boolean gating. Bar graph represents the number of CD122+ T-bet+ ILC1s, CD278+ GATA3+ 
ILC2s and IL-23R+ RORγt+ ILC3s identified in the lungs of a BCG i.n. inoculated mouse using the 
current antibody panel.   
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3.2.5 IL-23R staining was not successful  
Very few CD122- CD278- ILCs from the ILC subset surface marker fidelity test expressed IL-
23R (Figure 5- Figure 7), consequently, it was important to confirm that the lack of IL-23R+ 
ILC3s was not due to insufficient IL-23R staining. IL-23R is essential for the maintenance of 
a T helper 17 cell phenotype which are induced during mycobacterial infections; therefore, if 
IL-23R staining was successful it was hypothesised that an IL-23R+ population of live, fixed, 
CD45+ lymphocytes would be present (89,90). If there was no distinct live, fixed CD45+ IL-
23R+ lymphocyte populations, this would indicate that IL-23R staining was unsuccessful. As 
depicted in (Figure 8), IL-23R staining was unsuccessful as there was no difference between 
IL-23R staining of live, fixed CD45+ lymphocytes from the sample when compared to the IL-
23R FMO. Similar results were also seen when the ILC subset surface marker fidelity test was 
repeated on a further two BCG Pasteur i.n. inoculated mice (data not shown).  
Figure 8. IL-23R staining during the ILC subset surface marker fidelity test was unsuccessful. 
Cells were derived from a BCG i.n. inoculated mouse. Events were acquired using a BD LSR 
Fortessa. Initially cells were gated on time, followed by FSC and SSC singlet gates. Lymphocytes 
were then gated on, followed by live, fixed CD45+ cells. Cells were then gated on the expression of 
IL-23R. Histogram depicts the overlay of IL-23R staining of CD45+ live, fixed lymphocytes from 
the sample (red) and the IL-23R FMO (blue). 
 
These results indicate that further optimisation of the IL-23R staining protocol is required to 










marker to identify ILC3s; however, due to time constraints further optimisation was not 
possible. In addition, there were still extremely low numbers of ILC1s and ILC3s in the lungs 
of a BCG i.n. inoculated mouse that expressed both the ILC subset specific surface markers as 
well as the respective ILC subset specific transcription factors. Consequently, it was determined 
that it was not feasible to sort ILCs into subsets using the selected ILC subset specific surface 
markers (CD122, CD278 and IL23R). Instead total ILCs could still be used to establish a growth 
inhibition assay.  
3.3 Establishment of a mycobacterial growth inhibition assay  
Like T and B cells, ILCs are not considered to be phagocytic and therefore, are not expected to 
engulf mycobacteria or inhibit the growth of mycobacteria directly. However, following BCG 
i.n. inoculation ILC populations have been discovered to accumulate in the lungs of mice and 
upregulate IFNγ (2). IFNγ plays a number of roles during TB infections including activating 
phagocytic macrophages, resulting in the upregulation of over 200 genes (26). A number of 
these genes encode for the production nitric oxide which can enhance intracellular 
mycobacterial killing, consequently, it was hypothesised that total ILCs would enhance 
phagocyte killing of mycobacteria (26).  
To examine whether total ILCs could enhance intracellular mycobacterial killing, an in vitro 
growth inhibition assay needed to be established. To achieve this BCG-infected splenocytes 
were cultured alone or co-cultured with total sorted ILCs from a BCG i.n. inoculated mouse. 
Total sorted ILCs were theorised to enhance the anti-mycobacterial properties of phagocytic 
cells directly or act synergistically with lymphocytes to enhance the anti-mycobacterial 
properties of phagocytic cells. Consequently, total sorted ILCs were cultured with splenocytes 
as the spleen contains both phagocytic cells (macrophages and neutrophils) as well as 
lymphocytes (T and B cells) (91).  
 48 
3.3.1 Experimental design of the in vitro mycobacterial growth inhibition assay  
The experimental design of the in vitro mycobacterial growth inhibition assay is depicted in 
Figure 9 and will briefly be explained below.  
Mice were i.n. inoculated with 5x105 CFU of BCG Pasteur while naïve mice were also age-
matched. Four weeks later, at the peak of the ILC effector response, the lungs were harvested 
from BCG-inoculated mice and the spleens were harvested from naïve mice (2). Single cell 
suspensions were generated. Only the single cell suspension containing lung cells from BCG 
i.n. inoculated mice was stained with biotinylated antibodies against lineage markers before 
lineage positive cells were magnetically depleted, as total ILCs were only identified and sorted 
from BCG i.n. inoculated murine lung cells. Magnetic depletion removed unwanted lineage 
positive cells resulting in an improvement in the efficacy of the sort and purity of the final sort 
product. The remaining lineage negative cells were stained with antibodies against the ILC 
surface markers (Table 4) before total ILCs were sorted using a BD FACS Aria Fusion.  
Previous growth inhibition assays have demonstrated that splenocytes from a BCG s.c. 
inoculated mouse can significantly inhibit BCG growth in vitro, compared to splenocytes from 
a naïve mouse (74). Consequently, in this present study splenocytes from a BCG Pasteur s.c. 
inoculated mouse were used as a positive control and splenocytes harvested from a naïve mouse 
acted as a negative control (Table 9). Splenocytes acted as a source of both phagocytes and 
lymphocytes. 
To date, no published data from growth inhibition assays have previously assessed the ability 
of splenocytes derived from a BCG i.n. inoculated mouse to inhibit the growth of mycobacteria, 
however, BCG i.n. inoculation has been shown to induce significantly higher levels of splenic 
IFNγ-producing CD4+ and CD8+ T cells compared to naive mice (92). Therefore, splenocytes 
from a BCG i.n. inoculated mouse cultured without lung cells and acted as another positive 
control (Table 9) (92).  
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The ideal negative control for total sorted lung ILCs from BCG i.n. inoculated mice cultured 
with BCG-infected splenocytes would be total sorted lung ILCs from a naïve mouse cultured 
with BCG-infected splenocytes; however, as there were not enough total ILCs present in the 
lungs of a naïve mouse to sort, this was not feasible. As an alternative, TLC from a naïve mouse 
were cultured with BCG-infected splenocytes (Table 9).  
Lineage positive cells from a BCG i.n. inoculated mouse were kept after the lineage depletion 
and cultured with BCG-infected splenocytes which acted as another positive control as IFNγ-
producing effector CD4 T cells have previously been discovered to accumulate in murine lungs 
from 15-90 days post mycobacterial infection (Table 9) (93,94).  
All of the wells containing the cells were infected with BCG tdTomato at a MOI of 1:3450 
(BCG CFU : splenocytes) as MOIs of 1:1500 - 1:50,000 have previously been used to detect a 
significant enhancement in the ability of splenocytes derived from BCG s.c. vaccinated mice to 
inhibit the growth of BCG Pasteur Aeras, compared to splenocytes derived from saline treated 
mice (75). Based on previously established in vitro growth inhibition assay methods, cells 
cultures were incubated for 4 days (74,75,95). Following the incubation, the cells were lysed to 
release the intracellular mycobacteria and cell lysates were plated onto 7H11 agar plates 
supplemented with OADC. Two to three weeks later when colonies were visible, BCG 
tdTomato colonies were enumerated.  
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Figure 9. Experimental procedure for ILC in vitro MGIAs. Mice were i.n. inoculated with 5x105 
CFU of BCG Pasteur, naïve mice were also aged matched. Four weeks later the lungs and spleen 
were harvested from naïve and BCG Pasteur inoculated mice. Single cell suspension were then 
created. Only the single cell suspension from the BCG i.n. inoculated mice were stained with 
antibodies against lineage markers and underwent lineage depletion before cells were stained with 
surface markers. Total ILCs were then sorted using a BD FACS Aria Fusion. Splenocytes and lung 
cells were infected with BCG tdTomato at a MOI 1 CFU to 3450 splenocytes. After 4 days in 
culture the cells were lysed. Cell lysates were either spread directly onto 7H11 agar plates or serial 
dilutions of the cell lysates were spot plated onto 7H11 agar. Individual colonies were enumerated 
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Table 9. Sample and controls for the in vitro MGIAs. Splenocytes acted as a source of both 
phagocytes and lymphocytes. 
 
3.3.2 Gating strategy to sort live total murine lung ILCs 
Lung cells pooled from eight BCG Pasteur i.n. inoculated mice were stained with a viability 
dye and antibodies against lineage markers, CD45 and CD127 (Table 4). Two singlet gates 
were used to remove doublets before lymphocytes were gated on (Figure 10A- 10C). Live cells 
were gated on (Figure 10D) followed by CD45+ lineage- ILCs (Figure 10E)(80). Total ILCs 
were further classified as CD127+ cells (Figure 10F) (81).  
 Cells cultures  
Sample Total sorted ILC from BCG i.n. 
inoculated mouse 
Splenocytes from naïve mouse 
Positive 
Controls 
Lineage positive cells from BCG i.n. 
inoculated mouse 
Splenocytes from naïve mouse 
Splenocytes from BCG s.c. inoculated 
mouse 
 





TLC from naïve mouse Splenocytes from naïve mouse 
Splenocytes from naïve mouse  
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Figure 10. Representative biaxial dot plots depicting the gating strategy for sorting total ILCs 
from murine lungs. Lung cells were pooled from eight BCG i.n. inoculated mice. Cells were 
stained with a viability dye, and antibodies against: CD45, lineage markers and CD127. Cells were 
gated on using both FSC (A) and SSC (B) singlet gates. Lymphocytes were identified by FSC-A 
and SSC-A and gated on (C). Live cells were gated on (D). Lineage-, CD45+ cells were then gated 
on (E) followed by CD127+ cells (F).  
 
3.3.3 Purity of total ILC sorts  
To determine the purity of the sorted total ILCs ~1000 total sorted ILCs were re-acquired and 
analysed using the same gating strategy as shown in Figure 10. Representative biaxial dot plots 
show 1000 re-acquired events (Figure 11) from the same total ILC sorted population sorted for 
the first growth inhibition assay (Figure 10). The overall purity of sorted total ILCs was high 
as all gates contained greater than 90% the cell populations of interest, with the exception of 
the CD127 gate where only 89.3% of the CD45+ lineage negative cells were CD127+ (Figure 
11). There was slightly higher levels of contamination from CD45- lineage+ populations during 
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ILCs were CD45+ lineage negative, however, 99% of the sorted total ILCs reacquired were 
CD127+, indicating that a purity was still maintained during the fourth sort (data not shown).  
There were insufficient sorted total ILCs during the second and third ILC sorts to assess the 
purity of the sorted total ILCs; however, the same gating strategy and antibodies were used so 
it is likely that the sorted total ILCs were of a similar sort purity as the sorted total ILCs during 
the first and last sorts.  
Figure 11. Re-acquired total ILC sort product purity. Representative biaxial flow plots showing 
1000 re-acquired events from the same total ILC sorted population sorted in Figure 10. Gates were 













































3.4 Assessment of ILC enhanced splenocyte killing of 
mycobacteria 
3.4.1 ILCs did not enhance splenocyte killing of mycobacteria  
Murine lung ILCs have previously been discovered to upregulate IFNγ following BCG i.n. 
inoculation, therefore, it was hypothesised that ILCs would act as a conduit through the 
activation of phagocytic cells to indirectly enhance splenocyte killing of mycobacteria (2).  
Results pooled from the four independent growth inhibition assays can be seen in Figure 12. 
Total sorted ILCs pooled from BCG i.n. inoculated mice cultured with BCG-infected 
splenocytes did not reduce the number of BCG tdTomato CFU/mL compared to when BCG-
infected splenocytes were cultured alone. These results imply that ILCs did not enhance 
splenocyte killing of mycobacteria; however, it is important to note that there was high 
variability in the number of BCG tdTomato CFU/mL detected between technical replicates, 
indicating that the assay was poorly reproducible (Figure 12A). 
It was expected that total sorted ILCs from BCG i.n. inoculated mice would enhance splenocyte 
killing of mycobacteria compared to TLC isolated from a naïve mouse as murine lung ILC 
effector functions have been discovered to peak four weeks after BCG i.n. inoculation (2). 
Conversely, lung cells from a naïve mouse were never previously exposed to mycobacteria 
before being cultured with BCG-infected splenocytes. Therefore, it was theorised that TLC 
from a naïve would not generate a protective effector response or enhance splenocyte killing of 
mycobacteria. Results indicated that there was no significant difference in the number of BCG 
tdTomato CFU/mL when ILCs were cultured with BCG-infected splenocytes compared to 
when TLC isolated from naïve mice were cultured with BCG-infected splenocytes (Figure 
12B).  
It was also hypothesised that lineage positive cells from a BCG i.n. inoculated mouse would 
enhance splenocyte killing of mycobacteria to a greater extent than TLC from a naïve mouse 
but to a similar extent as total sorted ILCs, as IFNγ-producing effector CD4 T cells have 
 55 
previously been discovered to accumulate in murine lungs from 15-90 days post mycobacterial 
infection (93,94). However, there was no difference in the number of BCG tdTomato CFU/mL 
when BCG-infected splenocytes were cultured with lineage positive cells from BCG i.n. 
inoculated mice, TLC from a naïve mouse or sorted total ILCs from a BCG i.n. inoculated 
mouse (Figure 12B).  
Studies developing in vitro growth inhibition assays have shown that splenocytes from BCG 
s.c. inoculated mice can significantly inhibit the growth of BCG in comparison to splenocytes 
from a naïve mouse (74). Although growth inhibition assays have not previously assessed the 
ability of splenocytes derived from a BCG i.n. inoculated mouse to inhibit the growth of 
mycobacteria, mice i.n. inoculated with BCG have been discovered to have significantly higher 
levels of IFNγ-producing splenic CD4+ and CD8+ T cells compared to naïve mice (92). 
Therefore, it was hypothesised that splenocytes derived from both BCG s.c. and i.n. inoculated 
mice would kill BCG tdTomato colonies more efficiently than splenocytes harvested from a 
naïve mouse. However, no difference in the number of BCG tdTomato CFU/mL between BCG-
infected splenocytes sourced from either naïve, BCG i.n. or s.c. inoculated mice was detected 
(Figure 12A). Additionally, there was high variability between the number of BCG tdTomato 
CFU/mL detected between technical replicates. Further optimisation of the assay is therefore, 






Figure 12. Sorted total ILCs co-cultured with splenocytes from a naïve mouse did not enhance 
mycobacterial killing. TLC from a naïve mouse (negative control), lineage positive cells from 
BCG Pasteur i.n. inoculated mice (positive control) and total sorted ILCs from BCG Pasteur i.n. 
inoculated mice (sample) were cultured with BCG-infected splenocytes at a ratio of 1:166 (lung 
cells to splenocytes). 1x106 splenocytes from naïve (negative control), BCG Pasteur i.n. and s.c. 
inoculated mice (positive controls) were also cultured but without the addition of lung cells. All cell 
cultures were infected with BCG tdTomato at a MOI of 1:3450 (CFU : splenocytes). Following the 
four day culture, cells were lysed and cell lysates were plated onto 7H11 agar supplemented with 
OADC. BCG tdTomato CFU were enumerated and then converted into BCG tdTomato CFU per 
mL of culture. Kruskal-Wallis test followed by Dunn’s multiple comparison test were used to 
identify differences in the number of BCG tdTomato CFU/mL between groups. All differences 
were non-significant (p>0.05). Each dot represents an individual well in the culture plate. n=9-14 
replicates per group. Bars indicate median of replicates within each group. Data represents four 
independent experiments. ILC co-cultured with splenocytes from a naïve mouse did not enhance 
mycobacterial killing (A). No difference in the number BCG tdTomato CFU/mL were detected 
between when lung cells were cultured with BCG-infected splenocytes compared to when BCG-































3.4.2 Increasing the ratio ILCs to splenocytes did not enhance mycobacterial killing….…. 
Although total sorted ILCs from BCG i.n. inoculated mice were not shown to enhance 
splenocyte killing at a ratio of 1:166 (ILCs to splenocytes), it was hypothesised that increasing 
the ratio of ILCs to splenocytes from 1:166 to 1:83 or 1:42 may enhance splenocyte killing as 
there would be proportionally more effector and IFNγ-producing ILCs compared to 
splenocytes.  
The effect of increasing the ratio of TLC from a naïve mouse and lineage positive cells from a 
BCG i.n. inoculated mouse to BCG-infected splenocytes was also assessed. It was hypothesised 
that altering the ratio of TLC from a naïve mouse to BCG-infected splenocytes would not alter 
splenocyte killing of mycobacteria as these cells had never been pre-exposed to mycobacteria 
and therefore, would not be able to generate an effector response that would enhance splenocyte 
killing of mycobacteria. In comparison, lineage positive lungs cells from BCG i.n. inoculated 
mice were theorised to enhance splenocyte killing of mycobacteria as IFNγ-producing effector 
CD4 T cells have previously been discovered to accumulate in murine lungs from 15-90 days 
post mycobacterial infection (93,94). Therefore, it was hypothesised that increasing the ratio of 
lineage positive lungs cells to BCG-infected splenocytes would enhance splenocyte killing of 
mycobacteria as there would be proportionally more effector lineage positive cells compared 
to BCG-infected splenocytes.  
There was no difference in splenocyte killing of mycobacteria when the ratio of total sorted 
ILCs to BCG-infected splenocytes was altered, however, there was high variability in the 
number of BCG tdTomato CFU/mL detected between technical replicates (Figure 13). These 
results indicate that a higher ratio of ILCs to splenocytes may be required to detect ILC 
enhancement in splenocyte killing of mycobacteria. 
As expected, there was no difference in the number of BCG tdTomato CFU/mL when the ratio 
of TLC to BCG-infected splenocytes was altered (Figure 13). There was also no difference in 
the number of BCG tdTomato CFU/mL when the ratio of lineage positive lung cells from a 
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BCG i.n. inoculated mouse to BCG-infected splenocytes was increased from 1:83 to 1:42. 
There was a statistically significant increase in the number of BCG tdTomato CFU/mL when 
the ratio of splenocytes to lineage positive lung cells from a BCG i.n. inoculated mouse was 
increased from 1:83 to 1:166 (p=0.0195) (Figure 13). These results indicate that there was a 
greater enhancement in splenocyte killing when lineage positive cells were cultured with BCG-
infected splenocytes at a 1:83 ratio compared to a 1:166 ratio, however, as there was high 
variability between both technical and individual replicates this enhancement in splenocyte 
killing is most likely not biologically relevant. 
Figure 13. Increasing the ratio of ILCs to BCG-infected splenocytes did not alter 
mycobacterial killing. Sorted ILCs from BCG i.n. inoculated mice, TLC from a naïve mouse and 
lineage positive cells isolated during the lineage depletion of lung cells from a BCG i.n. inoculated 
mice were cultured at ratios: 1:42, 1:83 and 1:166 with BCG-infected splenocytes. All cultures were 
infected with BCG tdTomato at an MOI of 1:3450 (BCG : splenocytes). After a 96-hour incubation 
cells were lysed before cell lysates were plated onto agar. BCG tdTomato CFU were counted and 
then converted into BCG tdTomato CFU per mL of culture. Kruskal-Wallis test and the post hoc 
Dunn’s multiple comparison test were conducted to identify differences between groups. * 
p=0.0195. Where significance is not labeled, differences between groups was non-significant 
(p>0.05). Each dot represents an individual well in the culture plate. n=9-14 replicates per group. 
Bars indicate median of replicates within each group. Data represents four independent 
experiments. 
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3.4.3 BCG tdTomato colonies may have ejected the plasmid containing the tdTomato 
reporter during the 3rd and 4th in vitro MGIAs 
There was the possibility that lung cells from BCG Pasteur i.n. inoculated mice and splenocytes 
from BCG Pasteur i.n. and s.c. inoculated mice might harbor live intracellular BCG Pasteur and 
that BCG Pasteur colonies might grow when the cell lysates were plated onto 7H11 agar. 
However, it was possible to differentiate between any BCG Pasteur colonies (in vivo vaccine) 
and BCG tdTomato colonies (in vitro challenge) as BCG tdTomato contains a plasmid that 
encodes the red reporter gene; tdTomato, resulting in pink colonies.  
During the first and second growth inhibition assays, white colonies were observed on 7H11 
agar plates that had been spread with cell lysates from culture wells containing lineage positive 
cells and BCG tdTomato infected splenocytes. This implied that some BCG Pasteur colonies 
had survived intracellularly within lineage positive cells and consequently grew when cell 
lysates were plated onto 7H11 agar.  
Unexpectedly, white colonies were discovered on all 7H11 agar plates from the final two 
growth inhibition assays, including plates that had been spread with cell lysates containing 
either BCG tdTomato-infected splenocytes from a naïve mouse or TLC from a naïve mouse 
cultured with BCG tdTomato-infected splenocytes from a naïve mouse. As these cells were 
from mice that had never been exposed to BCG Pasteur, white colonies should not have grown 
on those particular plates.  
There were two hypotheses for the increased percentage of white colonies. Firstly, all the wells 
of the culture plates during the third and fourth assays may have become contaminated with 
BCG Pasteur, resulting in both white and pink colonies being present on all 7H11 agar plates. 
Alternatively, some of the of the tdTomato-BCG from the frozen aliquots may have undergone 
plasmid curing and ejected the plasmid containing the reporter that encodes for the tdTomato 
gene, resulting in both white and pink colonies being found on all 7H11 agar plates from the 
third and fourth assays.  
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To determine if some of the BCG tdTomato colonies could have undergone plasmid curing a 
fresh aliquot of BCG tdTomato was defrosted, sonicated and diluted before being plated onto 
7H11 agar supplemented with OADC. Additionally, 50μl and 100μl of the BCG 
tdTomato/pIMDM suspension was cultured for four days to mimic the growth inhibition assay 







Figure 14. White colonies were still observed when a fresh aliquot of BCG tdTomato was 
plated onto agar. A fresh aliquot of BCG tdTomato was taken out of the -80oC freezer and was 
defrosted, and sonicated before BCG tdTomato was diluted 1 in 3450 in pIMDM. The BCG 
tdTomato/pIMDM suspension was vortexed before 50μl of BCG tdTomato/pIMDM suspension 
and 150μl of H20/tween 80 0.05% was spread onto 7H11 agar supplemented with OADC. 
Additionally, 100μl of BCG/pIMDM suspension and 100μl of H20/tween 80 0.05% was spread 
onto 7H11 agar supplemented with OADC. 50μl and 100μl of the BCG/pIMDM suspensions were 
also cultured in separate wells of a 48 well plate for 4 days. After the 4-day incubation the cells 
were lysed and 200μl of the cell lysates were spread onto 7H11 agar supplemented with OADC. 
Bar graphs represent white and pink BCG tdTomato CFU/mL when BCG/pIMDM suspensions 
were spread onto 7H11 agar with and without a 4-day incubation. 
 
White colonies were enumerated from agar plates that had been spread with cell lysates from 
both BCG tdTomato/pIMDM suspensions that had directly been plated and BCG 
tdTomato/pIMDM suspensions that were incubated for 4 days before being plated (Figure 14). 
These results implied that I could not rule out the possibility that some BCG tdTomato CFU 
0-day incubation 4-day incubation 
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had undergone plasmid curing during the third and fourth growth inhibition assays. 
Consequently, both white and pink colonies were counted during the third and fourth growth 
inhibition assays as BCG tdTomato colonies could no longer confidently be distinguished from 
BCG Pasteur colonies. 
Analysis of the data from the first/second and third/fourth growth inhibition assays revealed 
that the general trend of BCG growth inhibition between cell cultures was maintained across 
all assays, despite the fact that only pink colonies were counted during the first/second assays 
and both pink and white colonies were counted during the third/fourth assays (Appendix 6.2.1). 
Therefore, data from all four growth inhibition assays were pooled together; however, higher 
variability in the number of BCG tdTomato CFU/mL was detected between technical replicates 
in the third and fourth growth inhibition assays.  
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4 Discussion 
The BCG vaccine is the only vaccine available to prevent against TB (9). While BCG is 
effective at preventing TB in neonates, BCG provides unreliable protection against adult 
pulmonary TB (10). Therefore, a new efficacious vaccine is urgently required. Vaccine 
developments have been hindered as very little is known about which cell types and memory 
responses contribute to protection against mycobacterial infections following BCG vaccination. 
However, the recently discovered immune cell subset, ILCs, may be able to generate a 
protective immune response against mycobacteria since ILC1 and ILC3 subsets have been 
found to upregulate IFNγ production and accumulate in the lungs of mice vaccinated with BCG 
compared to naïve mice (2).  
It is still unknown whether BCG-driven ILC effector responses can enhance mycobacterial 
killing. Therefore, the aim of this project was to determine whether ILC1 and ILC3 subsets 
could enhance mycobacterial killing in vitro, which would reveal directly for the first time 
whether ILCs can elicit a protective immune response against mycobacteria. If ILCs from BCG-
vaccinated mice do enhance mycobacterial killing, in the future vaccines could be developed 
against adult pulmonary TB to enhance ILC associated protective immune responses. 
It is well established that ILCs can be broadly categorised into three subsets based on the 
expression of the canonical ILC transcription factors: T-bet, GATA3 and RORγt; however, 
transcription factor antibody staining results in cell death as both the cellular and nuclear 
membranes need to be permeabilised to allow sufficient entry of the intranuclear antibodies into 
the cytoplasm and nucleus of the cell (37). Instead, antibodies against surface proteins and 
receptors can be used to help categorise and sort live ILC subsets since cells do not need to be 
permeabilised. However, unlike the canonical ILC subset specific transcription factors, ILC 
subset specific surface markers are not well established and there is wide heterogeneity between 
studies with regarding the use of surface proteins and receptors to identify ILCs subsets. To 
assess the ability of ILC subsets to enhance mycobacterial killing, the first objective of this 
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project was to determine whether ILCs could accurately be sorted into subsets based on surface 
protein and receptor expression, thereby preserving their viability. If the expression of a surface 
marker aligned with the expression of the ILC subset specific transcription factor, this would 
indicate that this marker could confidently be used to identify an ILC subset. 
In vitro MGIAs can directly assess the ability of immune cells to kill intracellular mycobacteria. 
This is achieved by culturing mycobacterial infected immune cells for a period of time. 
Following the incubation, infected immune cell cultures can be plated onto agar. The ability of 
the immune cells to kill intracellular mycobacteria can be directly assessed by enumerating 
CFU. Therefore, the second objective of this project was to establish an in vitro MGIA, 
whereby, BCG-infected splenocytes were cultured alone or cultured with sorted ILCs subsets. 
Following culturing, cell cultures were lysed to release intracellular mycobacteria and cell 
lysates were plated onto agar. The ability of ILC subsets to enhance mycobacterial killing was 
assessed by the enumeration of visible BCG colonies two to three weeks later.  
4.1 Summary of findings from this project 
Results from this project indicated that the expression of CD122, CD278 did not align with the 
expression ILC subset specific surface markers: T-bet and GATA3 respectively, therefore, ILC 
subsets could not be confidently identified by these surface markers. Additionally, optimisation 
of IL-23R staining is required to assess the fidelity of this surface marker against the expression 
ILC3 transcription factor; RORγt. Due to the low fidelity of ILC subset specific surface markers 
with respect to transcription factor expression and that insufficient numbers of ILCs were 
identified in the lungs of a BCG-vaccinated mouse, sorting live ILCs into subsets was not 
feasible. Instead, sorted total ILCs were used to establish an in vitro MGIA to assess the ability 
of total ILCs to enhance mycobacterial killing.  
Although sorting and culturing of total ILCs was successful, no apparent enhancement in 
mycobacterial killing was detectable when sorted total ILCs were co-cultured with BCG-
infected splenocytes. However, there was high variability in the number of BCG tdTomato 
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CFU/mL detected between technical replicates indicating that the current in vitro MGIA 
protocol was poorly reproducible. 
4.2 Discussion surrounding the ILC subset surface marker 
fidelity test  
Subset-specific ILC surface markers are not well established and therefore, the aim of the ILC 
subset surface marker fidelity test was to determine whether the expression of the ILC subset 
specific surface markers aligned with the expression of the corresponding canonical ILC subset 
transcription factors.  
4.2.1 CD122 expression weakly aligned with T-bet expression 
IL-15 is a cytokine that is required for the survival and the development of group 1 ILCs (83). 
IL-15 binds to the IL-15 receptor which consists of a β chain known as CD122 (96). CD122 is 
only expressed on group 1 ILCs and has therefore, previously been used as a surface marker to 
identify both NK cells and ILC1s (97).  
Analyses of the ILC subset surface marker fidelity test revealed that only 45% of CD122+ ILCs 
solely expressed the canonical ILC1 transcription factor, T-bet. Alternatively, only 53% of 
Lineage- CD45+ T-bet+ ILCs expressed CD122, implying that nearly half of the T-bet+ ILCs 
could not be identified based on CD122 cell surface expression. Of the 10,808 CD122+ ILCs 
identified in the lungs of a BCG i.n. inoculated mouse, only 4939 CD122+ ILCs expressed T-
bet These results suggest that an alternative surface marker is required to identify ILC1s, as 
CD122 expression only weakly aligned with T-bet expression. 
The NK cell-associated marker NK1.1 could be used as an alternative surface marker to 
positively identify group 1 ILCs, as NK1.1 is expressed on ILC1s and NK cells (98). Some 
murine ILC3 populations have also been discovered to express NK1.1; however, ILC3 
populations could still be positively characterised by the expression of ILC3 subset specific 
surface markers (37). The exact function of NK1.1 is incompletely understood, however, NK1.1 
may contribute to the development and survival of NK cells (99). It should be noted though that 
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while the NK1.1 antigen is expressed by eight strains of mice including C57BL/6 mice, over 
120 strains of mice do not express the NK.1.1 antigen (100). Consequently, identifying group 
1 ILCs based on the expression of the NK1.1 marker would limit the reproducibility of future 
studies as other mycobacterial research groups using one of the >120 mouse strains that do not 
express NK1.1 would require an alternative marker to identify group 1 ILCs.  
It is also important to consider that while T-bet is considered the main canonical group 1 
transcription factors, Eomes, is also involved in the transcription regulation of NK cells and 
some ILC1s (37,83). When the fidelity of the CD122 surface marker was assessed against the 
expression of ILC subset transcription factors, Eomes expression was not included. 
Importantly, 49% of CD122+, CD278- IL-23R- ILCs did not express T-bet, GATA3 or RORγt, 
indicating that these cells were either regulated by alternative transcription factors or that these 
cells expressed too low of levels of T-bet, GATA3 or RORγt to be detected by flow cytometry. 
Consequently, it would be valuable to add Eomes to future antibody panels to help identify the 
phenotype of the 49% of CD122+, CD278- IL-23R- ILCs that did not express T-bet, GATA3 or 
RORγt. 
4.2.2 CD278 expression weakly aligned with GATA3 expression  
CD278 (ICOS) has previously been used as a marker to identify both human and murine ILC2s 
(85). ICOS and ICOS-L interactions provide survival signals and also regulate ILC2 cytokine 
production (85). Analyses of the ILC subset surface marker fidelity test in this thesis indicated 
that only 36% of CD278 expressing ILCs expressed the canonical ILC2 transcription factor; 
GATA3, indicating that more than 60% of CD278+ ILCs were not ILC2s (as defined by 
transcription factor expression). Additionally, only 10% of lineage- CD45+ GATA3+ ILCs 
expressed CD278, implying that nearly 90% of GATA3+ ILC2s could not be categorised based 
on CD278 expression. Of the 3372 CD278+ ILCs that were identified in the lungs of a BCG i.n 
inoculated mouse, only 1456 CD278+ ILCs expressed GATA3. Consequently, CD278 
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expression poorly aligned with GATA3 expression and therefore, an alternative marker is 
necessary to identify ILC2s.  
A promising alternative surface marker that could be used to identify ILC2s is T1/ST2. T1/ST2 
forms the ligand binding component of the IL-33R which is only expressed on the surface of 
ILC2s (37,101). IL33 and IL-33R interactions results in the activation of ILC2s (102). The 
T1/ST2 marker has also previously been discovered to be strongly associated with GATA3 
expression as the gene and protein levels of T1/ST1 in ILC2s isolated from conditional 
tamoxifen GATA3 deficient mice (GATA3fl/fl CreERT2) were significantly reduced compared 
to T1/ST1 levels in ILC2s isolated from GATA3 sufficient mice (GATA3fl/fl) (103). In addition, 
ST2+ ILC2 populations have previously been identified by flowcytometry using a commercially 
available anti-ST2 antibody (103,104). Therefore, T1/ST2 could be an ideal marker to 
positively identify ILCs since T1/ST2 is associated with GATA3 expression and is only 
expressed by ILC2s.  
4.2.3 Low IL-23R staining efficacy 
IL-23R was hypothesised to be a useful marker to identify ILC3s since IL-23R is solely 
expressed on ILC3s (37). Additionally, IL-23 can promote the differentiation of ILC1s to ILC3s 
resulting in the upregulation of RORγt, indicating that the regulation of IL-23R and RORγt 
expression may be linked (52). However, analysis of the ILC surface marker fidelity test 
revealed that IL-23R staining efficacy was low, therefore, it could not be determined whether 
IL-23R expression aligned with the expression of the ILC3 transcription factor, RORγt.  
Further optimisation of IL-23R staining would be required to improve IL-23R staining efficacy. 
Such optimisation experiments could include staining the cells with the anti-IL-23R antibody 
in a smaller volume or increasing the staining incubation time. Alternatively, previous studies 
have successfully stained murine lung IL-23R+ ILC3s using an anti-IL-23R mAb conjugated to 
the fluorophore PE; therefore, an anti-IL-23R mAb conjugated to PE rather than BV650 could 
be tested to identify if there is any enhancement in IL-23R staining efficacy (2). 
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4.2.4 Transcriptional overlap between ILC subsets 
Analysis of the ILC subset surface marker fidelity test revealed that there was transcriptional 
overlap between ILC populations. A total of 0.7% of CD122+ ILCs expressed both T-bet and 
GATA3. Although GATA3 is essential for the development of ILC2s, GATA3 is also expressed 
by both ILC1 and ILC3 populations (105). In the absence of GATA3, bone marrow cells fail to 
give rise to CD127+ ILCs, which could explain why 0.7% of CD122+ ILCs expressed both T-
bet and GATA3 (103).  
Additionally, 11.7% of CD278+ ILCs expressed both GATA3 and RORγt transcription factors. 
Recent research has identified a highly inflammatory ILC2 population (iILC2), that can possess 
ILC3 like features (106). iILC2s can be activated by IL-25 and in response produce the type 2 
cytokine, IL-13, as well as the type 3 cytokine, IL-17 (106). More importantly iILC2s express 
both GATA3 and RORγt (106). Although iILC2s have not been studied in the context of 
mycobacterial infections there is a possibility that 11.7% of CD278+ GATA3+ RORγt+ 
populations may be iILC2s or a trans-differentiated ILC2/ILC3 populations.  
Transcription factor expression is widely considered the ‘gold-standard’ method to characterise 
ILCs into subsets. However, transcriptional overlap between ILC populations is a major 
limitation of this characterisation method. Alternatively, transcription factor expression, surface 
marker expression and cytokine production should all be considered when classifying ILC 
populations.  
Although the current ILC subset model has acted as a useful framework to help initially identify 
the broad function and phenotype of ILCs, the discovery of transdifferentiated populations of 
ILCs challenges the idea that ILC1, ILC2 and ILC3 populations are distinct subsets and instead 
promotes the idea that there is a continuum of highly diverse ILC populations. It is important 
to consider whether it is actually appropriate or possible to categorise and sort ILCs into three 
subsets due to the high transcriptional and functional diversity between ILC populations. The 
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findings from this thesis indicate that it is more appropriate and feasible to identify and sort 
total ILCs. 
Overall, owing to the low fidelity of ILC surface markers CD122 and CD278, with transcription 
factor expression and insufficient numbers of ILC subsets in the lung of a BCG-vaccinated 
mouse, it was concluded that sorting live ILCs into subsets would not be feasible. Instead, total 
ILCs were used to establish an in vitro MGIA.  
4.3 Rationale for the establishment of an in vitro MGIA  
IFNγ is a key cytokine that can activate macrophages resulting in the upregulation of over 200 
genes, some of which are involved in the production of nitric oxide and oxygen free radicals 
which aid in the killing of intracellular mycobacteria (29). The Kirman Laboratory had 
previously shown that BCG i.n. inoculation can drive the accumulation of IFNγ-producing 
ILC1 and ILC3 populations in the lungs of mice (2). Therefore, it was hypothesised that BCG-
activated murine lung derived ILCs could enhance the anti-mycobacterial properties of 
phagocytic immune cells, resulting in enhanced killing of intracellular mycobacteria. To assess 
the ability of total sorted ILCs from the lungs of BCG-inoculated mice to enhance intracellular 
mycobacterial killing an in vitro MGIA was established.  
4.4 Discussion surrounding the in vitro MGIA 
4.4.1 ILCs did not enhance splenocyte killing of mycobacteria  
It was hypothesised that total sorted ILCs from BCG i.n. inoculated mice would enhance 
splenocyte killing of mycobacteria as BCG inoculation has been shown to activate ILC effector 
cell functions which theoretically would enhance phagocytic cell function. However, there was 
no significant difference in the number of BCG CFU/mL when BCG-infected splenocytes from 
a naïve mouse were cultured alone compared to when BCG-infected splenocytes were co-
cultured with sorted total ILCs from BCG i.n. inoculated mice. This implied that at a 1:166 
ratio of ILCS to splenocytes, ILCs did not enhance splenocyte killing of mycobacteria.  
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The role that the tissue microenvironment plays on the plasticity, phenotype and function of 
ILCs has only recently been discovered; however, ILCs may not have been able to reproduce 
the same effector functions in vitro as have been described in vivo due to the absence of the 
tissue microenvironment (2). Adoptive transfer of splenic RORcfm+ (fate mapped) ILC3s from 
Rag-/- mice (lacking T and B cells) into recipient mice Rag2-/- Il2rg-/- (lacking T and B cells as 
well as ILCs) revealed that the transferred RORcfm+ ILC3s were distributed throughout the body 
into various organs including the liver, lung and small intestine (107). Five weeks after the 
initial transfer, the RORcfm+ ILC3s had developed different phenotypes and functions 
depending on what organ and tissue microenvironment they were in, indicating that tissue 
microenvironment plays an important role in determining the phenotype and function of ILCs 
(107). Consequently, BCG-activated murine lung ILCs may have been unable to respond or 
produce the same effector cytokines when cultured with splenocytes in vitro as they would in 
vivo in the lung. This may have led to the failure to enhance mycobacterial killing when ILCs 
were co-cultured with splenocytes.  
To identify whether the in vitro culturing microenvironment had reduced ILC effector 
functions, RNA sequencing of ILCs co-cultured with splenocytes for four days could be 
compared to RNA sequencing of ILCs isolated freshly from a BCG i.n. inoculated mouse. If 
levels of IFNγ as well as ILC activation markers, including CD127, were reduced in the four 
day cultured ILCs compared to freshly isolated ILCs from a BCG i.n. inoculated mouse this 
would indicate that ILC effector functions may have been affected by the microenvironment 
(82). 
4.4.2 Ability of ILCs to survive in culture  
Although no apparent enhancement in mycobacterial killing was detectable when ILCs were 
co-cultured with splenocytes, ILCs may not have been able to survive for the full four days of 
culturing. Therefore, ILC enhancement of splenocyte killing could have been diminished 
compared to if ILCs had survived the entire culture period. In the future the length of culturing 
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could be reduced to determine if the culturing length did effect the growth inhibition of 
mycobacteria when sorted total ILCs were co-cultured with BCG-infected splenocytes. 
Previous studies have successfully cultured murine fetal liver RORγt+ ILCs with feeder cells as 
well as IL-2, IL-7 in vitro for 12 days, indicating that in vitro culturing ILCs is possible (108). 
Although splenocytes from a naive mouse would act as a source of cytokines, additional 
cytokines like IL-2, IL-7 as well as IL-15 could be added to the cultures to promote ILC survival 
in vitro (45). 
4.4.3 Increasing the ratio of ILCs to splenocytes did not result in a dose dependent change 
in mycobacterial killing 
While no enhancement of mycobacterial growth inhibition was detected when total sorted ILCs 
were cultured with BCG-infected splenocytes at a ratio of 1:166, it was hypothesised that 
increasing the ratio of ILCs to BCG-infected splenocytes from 1:166 to 1:83 or 1:42 may 
enhance splenocyte killing as there would be proportionally more effector and IFNγ-producing 
ILCs compared to BCG-infected splenocytes. However, there was no significant difference in 
the number of BCG tdTomato CFU/mL when splenocytes were cultured with ILCs at the ratios 
of: 1:44, 1:83 or 1:166. These findings indicate that a higher ratio of ILCs to BCG-infected 
splenocytes may be required to detect an enhancement in splenocyte killing of mycobacteria in 
vitro. 
As murine lung ILCs have been discovered to produce IFNγ in vivo following BCG-inoculation 
it is important to relate the ratios of ILCs cultured with splenocytes in vitro to the ratio of ILCs 
to phagocytes in vivo. Although the ratio of ILCs to phagocytes in the lungs of a 4-week BCG-
inoculated mouse has not been directly assessed, previous work has indicated that 
approximately 2.6x106 total ILCs and 3.8x106 phagocytes, including: alveolar macrophages, 
interstitial macrophages and neutrophils were identified in the lungs of 1-week BCG Pasteur 
mice (2,109). Therefore, the approximate ratio of total ILCs to phagocytic cells in the lungs of 
1-week BCG Pasteur i.n. inoculated mice was 1: 1.5.  
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It is important to note that in this thesis only 4.2x104 total ILCs were identified in the lungs of 
a 4-week BCG i.n. inoculated mouse which is considerably lower than the 2.6x106 total ILCs 
that were identified in the lungs of 1-week BCG i.n. inoculated mice in the Steigler et al., study 
(2). A more extensive array of antibodies against lineage markers was used to gate out lineage 
positive cells in this thesis compared to the Steigler et al., study, which could have contributed 
to the difference seen in the number of total ILCs identified in the lungs of BCG-inoculated 
mice (2). Consequently, the true in vivo ratio of ILCs to phagocytes may be lower than 1: 1.5. 
The approximate in vivo ratio of ILCs to phagocytes; 1:1.5, is considerably higher than the 
ratios used in vitro (1:44, 1:83 and 1:166). It is also important to note that not all splenocytes 
are phagocytes and therefore, the in vitro ratio of ILCs to phagocytes may be closer to the in 
vivo ratio of ILCs to phagocytes. However, these findings indicate that lack of detection of ILC 
enhancement in mycobacterial killing may in part be because there was proportionally too few 
ILCs compared to splenocytes to produce a sizable effector response that could enhance 
splenocyte killing in vitro. In the future higher ratios of ILCs to splenocytes that better reflect 
the in vivo ratio of ILCs to lung phagocytes could be tested. Additionally, studies should be 
conducted to more accurately assess the ratio of ILCs to phagocytes in vivo in the lungs of 
BCG-inoculated mice.  
4.4.4 No difference in mycobacterial killing was detected between splenocytes from a naïve 
mouse and splenocytes from a BCG-inoculated mouse  
A previous in vitro MGIA that used the BACTECTM approach to quantify mycobacterial 
colonies, identified that splenocytes from a s.c. inoculated mouse significantly inhibited the 
growth of mycobacteria in comparison to splenocytes from a naïve mouse (75). However, such 
an enhancement in mycobacterial growth inhibition was not detected with the current in vitro 
MGIA whereby, the traditional plating technique was used to quantify mycobacterial CFU. 
This indicates that the current in vitro MGIA may have been insufficiently sensitive to detect 
any difference in the number of BCG tdTomato CFU/mL between BCG-infected splenocytes 
sourced from either naïve or BCG s.c. inoculated mice. In addition, there was high variability 
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in the number of BCG tdTomato CFU/mL detected between technical replicates in the current 
in vitro MGIA indicating that the protocol was poorly reproducible.  
The high variability in the number of BGC tdTomato CFU/mL between technical replicates in 
this current in vitro assay could be attributed to inaccuracies in the traditional plating approach 
to quantify mycobacterial CFU such as, pipetting technique and also visual counting of BCG 
colonies. BACTECTM tubes can detect growth of mycobacteria in culture via the utilisation of 
fluorescent oxygen sensors and are considered the ‘gold-standard’ of mycobacterial detection 
(110). One study indicated that although both the BACTECTM and the traditional plating 
approach could successfully detect serial dilutions of BCG Pasteur colonies, the coefficient of 
variance between technical replicates was only 2% using the BACTECTM approach in 
comparison, to 22% using the tradition plating approach (111). The Microbiology & 
Immunology Department has access to a MGIT fluorescence reader, therefore, in the future the 
BACTECTM tube approach could be used as an alternative way to quantify BCG CFU and 
reduce the variability between technical replicates. 
It is also important to consider that although the previous in vitro MGIA identified that 
splenocytes from a s.c. inoculated mouse could significantly inhibit the growth of mycobacteria 
in comparison to splenocytes from a naïve mouse, BCG growth inhibition was significantly 
impacted by the number of splenocytes as well as the number of bacteria (75). Out of the nine 
MOIs that were examined, a significant enhancement in mycobacterial growth inhibition was 
detected at only six MOIs (1:1500, 1:2500, 1:6000, 1:10,000, 1:50,000). One of the highest log 
reductions in BCG CFU was detected at an MOI of 1 BCG CFU to 10,000 splenocytes (0.815 
log reduction in BCG CFU) (75). In comparison, another MGIA also discovered that at a 
1:10,000 MOI (BCG CFU to splenocytes) splenocytes from a s.c. inoculated mouse could 
significantly inhibit the growth of mycobacteria in comparison to splenocytes from a naïve 
mouse (0.72 log reduction in BCG CFU) (95). In the current in vitro assay splenocytes were 
only cultured at an MOI of 1:3450, therefore, in the future it would be worthwhile to increase 
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the MOI to 1:10,000 to determine if a significant enhancement in mycobacterial killing could 
be detected when comparing splenocytes from a BCG s.c. inoculated mouse to splenocytes 
from a naïve mouse.  
4.5 Future directions  
4.5.1 Single cell RNA sequencing of murine lung ILCs ……… 
This project identified that ILC populations in the lungs of a BCG-inoculated mouse were 
transcriptionally heterogenic. To further explore the extent of this diversity single cell RNA 
sequencing of murine lung ILC populations could be undertaken. Single cell RNA sequencing 
has previously been conducted on B cells NK cells, macrophages, monocytes and plasmacytoid 
dendritic cells (112). Recently, single cell RNA sequencing has also been conducted on murine 
small intestinal ILCs, however, ILCs derived from the lungs of BCG-inoculated mice have not 
yet been sequenced (113). Understanding the functional and transcriptional diversity of BCG-
induced ILCs populations compared to ILCs from naïve mice may help to further elucidate the 
role ILCs play in response to mycobacterial infections. 
4.5.2 Adoptive transfer studies 
Adoptive transfer studies could act as an alternative method to assess ILC-enhanced growth 
inhibition of mycobacteria. Sorted total ILCs from BCG i.n. inoculated mice could be 
adoptively transferred into naïve mice, followed by a BCG challenge. Growth inhibition of 
mycobacteria could be identified by culturing BCG-infected lung suspensions in BACTECTM 
tubes to enumerate CFU. In this thesis 4.2x104 total ILCs were present in the lungs of a 4-week 
post BCG i.n. inoculated mouse, therefore, it is hypothesised that a similar number of ILCs 
would need to be adoptively transferred into a naïve mouse to see an enhancement in growth 
inhibition. On average in this project 50,000 total ILCs were sorted from the lungs of eight mice 
4-weeks post BCG i.n. inoculation. Therefore, approximately eight mice would be required to 
sort 4.2x104 total ILCs for one adoptive transfer. 
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Alternatively, expanding ILCs in vitro may reduce the number of mice needed for adoptive 
transfer studies. Although not well established sorted common lymphoid progenitor cells (CLP) 
from a mouse can be cultured and expanded in vitro with BCG, IL-7 and stem cell factor to 
differentiate and expand these CLPs into effector ILCs (114). Previous studies have identified 
that within six days of culturing an average of 8.5x104 Lin- Thy-1hi ILCs could be obtained 
(115). Therefore, CLPs from only one mouse would be required to obtain enough expanded 
ILCs for two adoptive transfers.  
4.6 Conclusion 
This research project identified that the surface markers: CD122, CD278, weakly aligned with 
expression of the canonical ILC1 and ILC2 transcription factors: T-bet and GATA3, indicating 
that these surface markers could not be confidently used to identify ILCs subsets. Low fidelity 
of ILC subset specific surface markers with respect to transcription factor expression and 
insufficient numbers of ILCs present in the lungs of BCG-inoculated mice meant that live ILC 
subsets could not be sorted. Instead, live total ILCs were sorted and used to establish an in vitro 
MGIA. 
To the best of our knowledge, the first ever in vitro MGIA was established to assess the ability 
of ILCs to enhance splenocyte killing. Although sorting and culturing of total ILCs was 
successful, there was high variability between BCG CFU/mL detected between technical 
replicates and no enhancement in mycobacterial killing was detected when ILCs were co-
cultured with splenocytes. However, this project has laid the foundations for further 
optimisation and development of in vitro MGIAs to help elucidate the role ILCs play in 
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6.1 Buffers and Media 
6.1.1 Phosphate buffered saline 
9.6 g of Dulbecco’s PBS powder (Gibco, Life Technologies) was added to 1 L of distilled water 
(dH2O) and magnetically stirred to make 1x PBS. The PBS solution was pH balanced between 
7.2-7.4 before the solution was filter sterilised under aseptic conditions.  
PBS/Tween-80 was prepared for dilution of BCG for mouse administration by the addition of 
0.05% v/v Polysorbate-80 (Tween-80; Sigma-Aldrich) to sterile 1x PBS. The PBS-Tween-80 
suspension was sterilised using a 0.22 μm filter (Corning).  
6.1.2 Cytometry and sorting buffers 
FACS buffer was prepared under aseptic conditions by the addition of 0.5% v/v fetal bovine 
serum (FBS; Gibco, Life Technologies) and 2 μM of Ethylenediaminetetraacetic acid (EDTA; 
Sigma Aldrich) to sterile 1x PBS.  
6.1.3 Easy Separation buffer for magnetic activated cell sorting  
EasySepTM buffer was prepared one to two hours before use under aseptic conditions by the 
addition of 2% v/v FBS (Gibco, Life Technologies) and 2 mM EDTA to 1x PBS.  10 μg/mL 
DNase I (Roche Diagnostics GmbH, Mannheim, Germany) was added to prevent cell clumping 
caused by lysed cells.  
6.1.4 Culture media  
All growth inhibition assay experiments used antibiotic free IMDM. Antibiotic free incomplete 
IMDM was prepared by adding 55 μM of 2-Mercaptoethanol (Gibco, Life Technologies) to 
IMDM GlutaMAX (1x) (Gibco, Life Technologies). Antibiotic containing iIMDM also 
contained 1% v/v penicillin/streptomycin solution (Gibco, Life Technologies). pIMDM was 
prepared by adding 55 μM of 2-Mercaptoethanol and 5% v/v FBS to IMDM GlutaMAX (1x), 
or complete (cIMDM) by the addition of 5% v/v FBS (Sigma Aldrich), 55 μM 2-
Mercaptoethanol and 1% v/v penicillin/streptomycin solution to IMDM GlutaMAX (1x).  
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6.1.5 Lung digestion buffer for antibody panel experiments 
Lung digestion buffer was prepared one to two hours before use by adding 2.4 mg of 
collagenase type 1 (Gibco, Life Technologies) and 0.12 mg DNase I (Roche Diagnostics 
GmbH) per mL of iIMDM. Alternatively, the lung digestion buffer for cell sorting experiments 
was prepared one to two hours before use by adding 0.185 mg liberase DH research grade 
(Roche Diagnostics GmbH) and 0.12 mg DNase I (Roche Diagnostics GmbH) per mL of 
iIMDM. 
6.1.6 Bacterial media 
BBL OADC (BBL, Becton, Dickinson & Co.) was initially purchased premade and was used 
to supplement 7H11 agar plates in the first growth inhibition assay.  
OADC was made in-house by dissolving 50 g Bovine Serum Albumin Fraction V (BSAF V; 
Roche Diagnostics GmbH) in 950 mL of dH20. Once the BSAF V had fully dissolved 8.5 g of 
NaCl (Merck & Company, New Jersey, USA) 20 g D-glucose (Sigma Aldrich), and 0.5 g oleic 
acid (Sigma Aldrich) were added to the solution. The solution was placed on a 30oC heating 
block and magnetically stirred until the oleic acid had dissolved. 40 mg catalase (Sigma 
Aldrich) was added and the solution was filter sterilised with a 0.22 μm membrane and stored 
at 4oC. A 5 mL aliquot of the solution was placed in a 37oC incubator overnight to detect 
potential contamination. In- house OADC was used to supplement 7H11 agar plates in the 
second, third and fourth growth inhibition assays. 
BBL Seven H11 agar (BBL, Becton, Dickinson & Co.) was used to culture and enumerate 
BCG. The agar was prepared by adding 19 g of the BBL Seven H11 agar powder to 900 mL of 
dH20 containing 5 mL of glycerol. The mixture was magnetically stirred until a smooth 
suspension was obtained. Without boiling, the agar was then autoclaved at 121oC for 10 
minutes. The autoclaved agar was kept in a 50oC water bath until plate pouring. Under aseptic 
conditions 100 mL of either the in-house OADC or the BBL OADC enrichment (BBL, Becton, 
Dickinson & Co.) per 1 L of agar was added. 20 mL of the agar was aseptically dispensed into 
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sterile plastic petri dishes. Agar plates were placed into sealed plastic bags, agar side up, and 
wrapped in aluminum foil to shield the plates from the light. The agar plates were stored at 4oC 
for no more than two weeks. Two plates were placed in a 37oC incubator for 48 hours to detect 
any contamination.  
For diluting and plating BCG, 0.05% v/v Polysorbate-80 (Tween-80; Sigma-Aldrich) was 
added to dH2O and sterilised using a 0.2 μm filter.  
6.2 Supplementary Figure 
6.2.1 General trend of BCG growth inhibition was maintained between all MGIAs…….. 
Supplementary Figure 1. General trend of BCG growth inhibition was maintained between all 
MGIAs. ILCs from BCG i.n. inoculated mice, TLC from a naïve mouse and lineage positive cells 
isolated during the lineage depletion of lung cells from a BCG i.n. inoculated mice were cultured 
at ratios: 1:42, 1:83 and 1:166 with BCG-infected splenocytes. Additionally, 5x105 and 1x106 BCG-
infected splenocytes from a BCG i.n. inoculated mouse were cultured without the addition of lung 
cells. All cultures were infected with a BCG tdTomato at an MOI of 1:3450 (BCG : splenocytes). 
After a 96-hour incubation cells were lysed before cell lysates were plated onto 7H11 agar. BCG 
tdTomato CFU were counted and then converted into BCG tdTomato CFU per mL of culture. Each 
dot represents an individual well in the culture plate. n=4-9 replicates per group. Bars indicate 
median of replicates within each group. Bar graphs show the general trend of BCG growth 
inhibition in the first and second MGIAs compared to the third and fourth MGIAs.  
